Minggu, 12 Desember 2021

Supplements To Increase Testosterone Ftm

Supplements To Increase Testosterone Ftm

Abstract

Nonsuppressed levels of testosterone are seen in up to a quarter of transgender women on gender-affirming feminizing hormonal treatment. Multiple factors contribute to this situation, including patient, medication, laboratory, and organ-specific concerns. We propose a stepwise approach to determine the etiology of nonsuppressed levels of testosterone in transgender women. This may lead to an appropriate feminizing hormonal therapy regimen and diagnosis of manageable medical conditions.

Transgender and gender diverse (TGD) people have gender identities that are not aligned with the sex recorded at birth. Gender-affirming care for TGD individuals can include medical and surgical interventions to better align physical characteristics with gender identity. Gender-affirming feminizing hormonal therapy (GAFHT) typically consists of estrogen and androgen- lowering or androgen-inhibiting therapy (Table 1). Estrogen exerts negative feedback at the hypothalamic-pituitary level, leading to decreased endogenous testosterone production from the gonads, along with feminizing effects by action at estrogen receptors. Current Endocrine Society guidelines recommend follow-up evaluation and sex hormone laboratory testing every 3 months during the first year on GAFHT [1]. Goal estradiol levels are 100 to 200 pg/mL and goal testosterone values are less than 50 ng/dL [1]. Expected changes on GAFHT include decreased libido and spontaneous erections, body composition changes including increased fat mass and decrease in muscle mass and strength, redistribution of body fat, breast development, skin softening, and hair changes including increasing softness and decreased terminal hair growth [2].

Table 1.

Estradiols and adjunctive agents used in feminizing hormonal treatment

Estradiols Typical Doses
Oral estradiol 2.0-6.0mg daily
Transdermal estradiol 0.025-0.2mg daily
Estradiol patch
Parenteral estradiol 2-10 mg weekly
Cypionate or valerate
Anti-androgens Typical doses
Spironolactone 100-300 mg daily
Nonsteroidal anti-androgens
Bicalutamide 25-50 mg daily
5-alpha reductase inhibitors
Finasteride 1-5 mg daily
Androgen-lowering agents Typical doses
GnRH analogs 3.75 mg SQ (SC) monthly or
Leuprolide 11.25 mg SQ (SC) 3-monthly
Cyproterone acetate 25-50 mg daily
Estradiols Typical Doses
Oral estradiol 2.0-6.0mg daily
Transdermal estradiol 0.025-0.2mg daily
Estradiol patch
Parenteral estradiol 2-10 mg weekly
Cypionate or valerate
Anti-androgens Typical doses
Spironolactone 100-300 mg daily
Nonsteroidal anti-androgens
Bicalutamide 25-50 mg daily
5-alpha reductase inhibitors
Finasteride 1-5 mg daily
Androgen-lowering agents Typical doses
GnRH analogs 3.75 mg SQ (SC) monthly or
Leuprolide 11.25 mg SQ (SC) 3-monthly
Cyproterone acetate 25-50 mg daily

Transformed from Hembree et al [1]

Table 1.

Estradiols and adjunctive agents used in feminizing hormonal treatment

Estradiols Typical Doses
Oral estradiol 2.0-6.0mg daily
Transdermal estradiol 0.025-0.2mg daily
Estradiol patch
Parenteral estradiol 2-10 mg weekly
Cypionate or valerate
Anti-androgens Typical doses
Spironolactone 100-300 mg daily
Nonsteroidal anti-androgens
Bicalutamide 25-50 mg daily
5-alpha reductase inhibitors
Finasteride 1-5 mg daily
Androgen-lowering agents Typical doses
GnRH analogs 3.75 mg SQ (SC) monthly or
Leuprolide 11.25 mg SQ (SC) 3-monthly
Cyproterone acetate 25-50 mg daily
Estradiols Typical Doses
Oral estradiol 2.0-6.0mg daily
Transdermal estradiol 0.025-0.2mg daily
Estradiol patch
Parenteral estradiol 2-10 mg weekly
Cypionate or valerate
Anti-androgens Typical doses
Spironolactone 100-300 mg daily
Nonsteroidal anti-androgens
Bicalutamide 25-50 mg daily
5-alpha reductase inhibitors
Finasteride 1-5 mg daily
Androgen-lowering agents Typical doses
GnRH analogs 3.75 mg SQ (SC) monthly or
Leuprolide 11.25 mg SQ (SC) 3-monthly
Cyproterone acetate 25-50 mg daily

Transformed from Hembree et al [1]

Testosterone levels on standard doses of estrogen therapy given to transgender women alone do not reliably reduce to values in the cisgender female reference range [3, 4]. The addition of anti-androgens and androgen-lowering therapies help further reduce testosterone levels or action and therefore also limits the dose of estrogen needed to induce feminizing physical changes [3, 4].

In a cohort of 98 transgender women on variable doses of spironolactone and estrogen, 25% did not suppress testosterone [5]. Baseline testosterone levels and spironolactone dosages do not predict successful suppression of testosterone levels. Another study of 229 transgender women in the European Network for the Investigation of Gender Incongruence (ENIGI) cohort showed that 7.9% of women on estrogen and variable anti-androgens (cyproterone acetate [CPA] or spironolactone) did not suppress testosterone [6]. Finally, 33% of transgender women in a cohort of 16 transgender women at University of California San Francisco who were on varying doses of estrogen and spironolactone did not achieve goal total testosterone levels, although only 6% of transgender women did not achieve goal levels of free testosterone [7].

As more transgender women seek care, a common question arises—why are testosterone levels nonsuppressed in up to a quarter of patients on GAFHT? Medical therapy plays a critical role in TGD persons to express their affirmed gender and reduce gender dysphoria. Proper workup of nonsuppressed testosterone levels in transgender women may have important long-term implications regarding appropriate feminizing hormonal therapy doses and early diagnosis of manageable medical conditions. In this paper, we propose an approach to determine causes of nonsuppressed testosterone in a patient on GAFHT (Fig. 1).

Figure 1.

Approach to nonsuppressed testosterone levels on GAFHT. Abbreviations: GAFHT, gender-affirming feminizing hormonal treatment; TT, total testosterone; T, testosterone; SHBG, sex hormone–binding globulin; LH, leutinizing hormone; GnRH, gonadotropin-releasing hormone; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; B-HCG, beta-human chorionic gonadotropin; 17-OHP, 17-hydroxyprogesterone; DHEA-S, dehydroepiandrosterone sulfate.

Approach to nonsuppressed testosterone levels on GAFHT. Abbreviations: GAFHT, gender-affirming feminizing hormonal treatment; TT, total testosterone; T, testosterone; SHBG, sex hormone–binding globulin; LH, leutinizing hormone; GnRH, gonadotropin-releasing hormone; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; B-HCG, beta-human chorionic gonadotropin; 17-OHP, 17-hydroxyprogesterone; DHEA-S, dehydroepiandrosterone sulfate.

Figure 1.

Approach to nonsuppressed testosterone levels on GAFHT. Abbreviations: GAFHT, gender-affirming feminizing hormonal treatment; TT, total testosterone; T, testosterone; SHBG, sex hormone–binding globulin; LH, leutinizing hormone; GnRH, gonadotropin-releasing hormone; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; B-HCG, beta-human chorionic gonadotropin; 17-OHP, 17-hydroxyprogesterone; DHEA-S, dehydroepiandrosterone sulfate.

Approach to nonsuppressed testosterone levels on GAFHT. Abbreviations: GAFHT, gender-affirming feminizing hormonal treatment; TT, total testosterone; T, testosterone; SHBG, sex hormone–binding globulin; LH, leutinizing hormone; GnRH, gonadotropin-releasing hormone; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; B-HCG, beta-human chorionic gonadotropin; 17-OHP, 17-hydroxyprogesterone; DHEA-S, dehydroepiandrosterone sulfate.

Case 1

A 28-year-old transgender woman was seen at the Mayo Clinic Transgender and Intersex Specialty Care Clinic to start GAFHT. She had a history of malnutrition due to avoidant/restrictive food intake disorder, with a body mass index of 17.23 kg/m2 at baseline. Other medical history included microcephaly and childhood growth hormone deficiency. Physical exam, including genital examination, was unremarkable other than microcephaly and lean body habitus. Baseline hormonal levels included an estradiol level of 26 pg/mL measured by liquid chromatography–mass spectroscopy (LC-MS), follicle-stimulating hormone (FSH) level of 5.0 IU/L, luteinizing hormone (LH) level of 3.5 IU/L, and total testosterone level of 701 ng/dL (by LC-MS), all within reference range for an individual recorded male at birth.

After addressing her nutritional concerns, she was initiated on low-dose spironolactone 25 mg daily and 2 mg of oral estradiol, with a plan to return for follow-up in the clinic. Despite achieving goal levels of estradiol (171 pg/mL) on escalating doses of estradiol and spironolactone, her follow-up laboratory values revealed her total testosterone level remained out of feminine goal range at 514 ng/dL. She reported positive feminizing changes including facial skin softness and breast tenderness, decreasing libido, and loss of spontaneous erections.

Case 2

A 24-year-old transgender woman was seen at the Transgender and Intersex Specialty Care Clinic for follow-up. After a comprehensive evaluation revealed an unremarkable medical history and physical examination (including normal genital exam), she was initiated on GAFHT including oral estradiol and spironolactone. Baseline laboratory testing done at Mayo Clinic prior to GAFHT included total testosterone level of 505 ng/dL (LC-MS) and undetectable estradiol measured by immunoassay.

Follow-up visits revealed no clinical feminization achieved despite increasing doses of estradiol and changing to a different preparation—injectable estradiol valerate. Given her nonsuppressed testosterone levels, her spironolactone was switched to leuprolide—22.5 mg injected every 3 months. With these medication changes, both her LC-MS bioavailable testosterone and LC-MS total testosterone remained out of goal at 105 ng/dL and 476 ng/dL, respectively. Additionally, laboratory testing revealed an LC-MS estradiol level of 244 pg/mL, LH level of 0.3 IU/L (reference range, 1.3-9.6 IU/L), and FSH of 0.3 IU/L (reference range, 1.2-15.8 IU/L). At this visit, she described minimal breast enlargement and tenderness. Her testosterone levels were confirmed on a second blood draw.

Medication Errors

An initial first step would be to consider medication-specific concerns. Determining adherence and confirming the dose taken can often reveal a straightforward reason for having higher-than-expected testosterone levels on GAFHT. Having patients bring or show their prescription along with associated supplies can help eliminate any confusion. Parenterally administered medications may often have challenges when considering self-administration, different available dose concentrations, and syringe sizes. A dispensed concentration of parenteral estradiol may also be different than the prescribed estradiol concentration due to insurance coverage.

Laboratory Testing Issues

Various assays (total, bioavailable, and free testosterone) can be used to measure circulating testosterone. Circulating testosterone can be unbound, albumin-bound, or sex hormone–binding globulin (SHBG)-bound [8]. Total testosterone measures all circulating testosterone, free testosterone measures unbound testosterone, while bioavailable testosterone measures unbound and albumin-bound testosterone. Through the free hormone hypothesis, unbound or free testosterone is thought to exert the biologic actions of testosterone [9]. In cisgender men, both total and free testosterone measurements can be indicators of androgen activity [10, 11]. Albumin does not have as high binding affinity to testosterone as SHBG and therefore dissociates freely, and this portion of circulating testosterone is thought to also be biologically active [12]. Thus, measurement of free and/or bioavailable testosterone assays can be valuable markers of testosterone activity if there is discordance in feminization and total testosterone levels.

When comparing total testosterone assays, the more common immunoassays generally have higher variability than mass spectrometry assays (gold standard for total testosterone) especially at low and high testosterone concentrations [12]. Given this variability, the Centers for Disease Control and Prevention offers certification of total testosterone assays through a hormone standardization program with a goal performance criterion limiting bias to ±6.4% [13].

SHBG abnormalities can lead to incongruence between total and free or bioavailable testosterone levels. Patients with elevated SHBG levels may have elevated total testosterone levels, while their bioavailable or free testosterone levels remain low or within the goal range. Thus, a potential cause of nonsuppressed total testosterone values may be elevated SHBG levels. SHBG elevation can be caused by aging, various medications (estrogen, anticonvulsants, and metformin), medical conditions (liver disease, hyperthyroidism, and HIV disease) [11]. Rarely SHBG polymorphisms are also responsible for a rise in SHBG levels [11]. Though an elevated SHBG by itself is not a medical contraindication to GAFHT, the etiology of the SHBG elevation should be considered. In this scenario, it is more appropriate to follow free or bioavailable testosterone levels, unaffected by SHBG.

Likewise, SHBG levels affect estradiol measurements [14]. If SHBG levels are elevated, total estradiol may be in range but may not reflect circulating levels of biologically active free estradiol. In circumstances in which patients have testosterone above goal range and feminization is not occurring as expected, targeting a higher total estradiol target or measuring free estradiol may be appropriate. If a patient is taking conjugated equine estrogens, it might be difficult to determine if they are receiving an adequate dose, as estradiol levels cannot be measured in these patients.

In summary, when considering nonsuppressed testosterone levels, laboratory testing issues are important to consider. If expected feminization is occurring while total testosterone remains high, measuring total testosterone on different assays is reasonable. Additionally, measuring free or bioavailable testosterone and SHBG levels may point to total testosterone not being the most reliable indicator of active androgens.

Gender-Affirming Hormone Therapy Preparations

Estrogen

Bioidentical 17-beta–estradiol is the preferred estrogen for GAFHT, thereby avoiding synthetic estrogens which could have higher thromboembolic and cardiovascular risks [15]. 17-beta-estradiol can be provided in oral, transdermal, or parenteral formulations (Table 1). Some patients place the oral tablet under the tongue to mimic sublingual route.

Oral administration is subject to significant first-pass metabolism (converted to estrone and estrone sulfate—significantly less potent estrogens than estradiol). Peak estradiol values occur several hours after ingestion and can remain raised for up to 12 hours before decreasing [16]. Sublingual administration of estradiol avoids first-pass metabolism, is rapidly absorbed, results in peak estradiol levels in 1 hour, and then decreases within 3 hours. In a small cohort of 10 transgender women, when comparing similar doses of oral to sublingual estradiol, sublingual estradiol had higher mean concentrations of serum estradiol levels than oral estradiol in the initial 8 hours after therapy [17]. Given these pharmacokinetics, once-daily oral and sublingual estradiol may not have optimal 24-hour coverage and may lead to testosterone escape through loss of inhibition of the hypothalamic-pituitary-gonadal axis.

Parenteral and transdermal preparations are thought not have a first-pass metabolism and do not affect liver protein synthesis as oral preparations do. Transdermal preparations typically peak within several hours of administration and typically last 7 days and are recommended to be applied once to twice per week depending on the manufacturer [16]. Patch and gel administration is associated with a high variation in circulating estradiol values—even within the same patient in cisgender women [18]. Areas of application may affect absorption with significant differences in bioavailability (scrotum, abdomen, buttocks regions have the highest absorptions). Other factors modifying absorption include variations in dermal blood flow (circadian differences), skin thickness, and dehydration or humidity. In this scenario of poor absorption, estradiol levels would be low along with the higher-than-expected testosterone levels.

Parenteral estradiol shows a peak of estradiol values in 2 to 4 days with an average duration of 7 to 11 days (depending on the specific preparation—valerate vs cypionate and its lipophilicity) [16]. Subcutaneous and intramuscular estradiol administration appear to have similar pharmacokinetics [16]. Measuring peak, mid-cycle, and trough estradiol levels may reveal intra-individual variation in absorption.

In summary, consideration of estradiol pharmacokinetics and application of therapy can reveal a reason for nonsuppressed testosterone levels. Providers can choose to adjust their prescription to avoid the phenomenon of testosterone escape. Oral or sublingual estradiol can be given twice daily in divided doses. A trial of transdermal estradiol applied at different body parts may reveal significant differences in absorption. Changing preparations or the route of estradiol may be another strategy to suppress testosterone if adequate estradiol absorption is not achieved.

Anti-Androgens and Androgen-Lowering Therapies

Anti-androgens and androgen-lowering therapies vary in their mechanisms to achieve desired feminization. Several classes of therapies are available—spironolactone, gonadotropin-releasing hormone analogs (GnRH), nonsteroidal anti-androgens, CPA, and 5-alpha reductase inhibitors (Table 1). Choice of adjunctive therapy may reflect region-specific regulatory approval, price, availability, adverse effect profile, and prescriber preference [19].

Spironolactone, the most common anti-androgen prescribed in the United States, limits androgens in multiple methods. It acts as an antagonist at the androgen receptor, may block testosterone synthesis at the 17-alpha hydroxylase, 17, 20-lyase enzymatic steps at the adrenal level, and additionally has a weak progestin action exerting negative feedback at the hypothalamic and pituitary levels, thereby lowering testosterone secretion from the gonads. Nonsteroidal anti-androgens also act as antagonists at the androgen receptor, though more potently.

GnRH analogs act at the hypothalamus, decreasing GnRH secretion and thereby decreasing gonadotropin (LH and FSH) secretion, which in turn leads to decreased testosterone synthesis. Cyproterone acetate (CPA), which is not approved in the United States by the Food and Drug Administration, is a potent progesterone receptor agonist that leads to suppression of the hypothalamic-pituitary-gonadal axis along with antagonistic effects at the androgen receptor level. Lastly, 5-alpha reductase inhibitors decrease the conversion of testosterone to the more potent dihydrotestosterone in androgen-sensitive target tissues and are often used to reduce androgen action in scalp hair follicles to limit alopecia.

When comparing GnRH analogs with CPA, similar levels of LH and testosterone suppression were achieved at 12 months on standard dosing in 40 transgender women in 1 study, although a more rapid suppression of LH and testosterone was found at 3 months in the GnRH agonist group [20]. Another study compared estradiol with spironolactone to estradiol with CPA to estradiol alone in a cross-sectional analysis. The lowest testosterone levels were found to be achieved in the CPA group, with the spironolactone group next, and finally the estradiol alone group [21]. Spironolactone use in transgender women has mostly led to lower levels in testosterone in most studies, although some studies show levels of testosterone that do not significantly lower when comparing estradiol to estradiol plus spironolactone therapy [4, 21]. The addition of 5-alpha reductase inhibitors seems to increase testosterone levels when combined with estradiol [4].

Therefore, choice of anti-androgen and androgen-lowering therapy may influence testosterone levels. However, due to the variation in anti-androgen mechanisms, individual responses to various preparations may vary considerably in serum testosterone levels and potential clinical feminization response.

Gonadal Pathology

Pathologic gonadal sources of testosterone production may also be discovered during GAFHT. In these cases, gonadotropin levels are typically low or suppressed, with testosterone levels that remain above goal range along with potentially inadequate feminization on GAFHT. Multiple case reports with testicular cancer have been reported in the literature diagnosed after initiation of GAFHT [22-24]. These cases were diagnosed due to elevated testosterone levels despite adequate estradiol levels and multiple high-dose anti-androgen medications, with stalled feminization. Low LH levels, testicular mass on exam, and nonrevealing adrenal workup leading to testicular imaging and relevant elevated tumor markers (lactate dehydrogenase, alpha-fetoprotein, and beta-human chorionic gonadotropin [β-HCG]) ultimately revealed the diagnosis [22-24].

Adrenal Pathology

Excess adrenal androgen production needs to be considered in patients with nonsuppressed testosterone levels despite adequate GAFHT. Similar to gonadal pathologies, LH levels would be low or suppressed along with inadequate feminization on GAFHT. Adrenal androgens such as dehydroepiandrosterone and dehydroepiandrosterone sulfate are precursors to testosterone synthesis and may be elevated. Adrenal pathologies can include congenital adrenal hyperplasia and androgen-producing adrenal tumors.

Nonclassic congenital adrenal hyperplasia 21-hydroxylase deficiency may be asymptomatic in transgender women, but many may have acne [25]. Diagnostic testing includes measuring 17-hydroxyprogesterone levels, baseline and with co-syntropin stimulation [25]. Pure androgen secreting adrenal tumors are infrequently reported, with co-secretion of cortisol being more common [26]. Presence of elevated androgen production and signs of rapid hypervirilization should prompt suspicion for adrenocortical carcinoma[26]. Imaging of adrenal glands may reveal adrenal enlargement and diagnostic testing should evaluate for adrenal hyperfunction.

Pituitary Pathology

A rare potential cause of nonsuppressed testosterone values may also be a functional pituitary gonadotroph adenoma (FGA) with hypersecretion of testosterone. A central cause can be suspected with elevated LH levels along with elevated testosterone levels despite adequate estradiol therapy. At the present time, no FGAs have been described in the literature in TGD individuals.

A review of FGAs reveals that most gonadotroph-secreting adenomas are not functional and adenomas secreting functional gonadotropins are exceedingly infrequent [27]. Most reports of functional gonadotroph adenomas are in cisgender women and are a clinical rarity in cisgender men. In those functional FGA cases, there is a universal elevation of FSH levels with variable LH and testosterone levels along with clinical manifestations of testicular enlargement due to the trophic effect of FSH and visual field deficits such as bi-temporal hemianopsia due to the pituitary adenoma [27]. These FGAs often have suprasellar or parasellar extension as compared to other pituitary adenomas [27].

Case 1 Resolution

We performed further testing on our patient with testosterone levels out of goal range despite adequate estradiol levels including bioavailable testosterone levels and SHBG. On a combination of spironolactone and estradiol therapy, her bioavailable testosterone was suppressed below the cisgender male range (reference range, 83-257 ng/dL). Her SHBG level was elevated to 99 nmol/L (reference range, 10-57 nmol/L). Simultaneously, she was admitted to the hospital for further management of her avoidant food intake disorder. After a 4-week inpatient admission and additional weight gain, she was subsequently discharged. Follow-up laboratory testing showed a total testosterone of 28 pg/dL and bioavailable testosterone of 3.6 pg/dL.

Her SHBG elevation was thought to be due to a combination of oral estradiol therapy and malnutrition. Therefore, not only was her total testosterone misleading, but her estradiol dose might have also been subtherapeutic with her elevated SHBG levels. Given her adequate feminization, a plan was made to adjust her GAFHT dosages to the target bioavailable testosterone and free estradiol values.

Case 2 Resolution

Given the combination of suppressed gonadotropin and elevated testosterone levels, we ordered testicular imaging, and tumor marker levels including alpha-fetoprotein and β-HCG. Scrotal ultrasound revealed a left-sided 2.7-cm hypoechoic mass suspicious for a primary testicular neoplasm. β-HCG levels were elevated on multiple draws—4.9 and 4.4 IU/L (reference range, <1.4 IU/L). Due to these findings, she was referred to Urology for further management for concern of a germ cell tumor.

After negative whole-body imaging looking for metastatic involvement, she underwent a bilateral orchiectomy. Her contralateral testis was removed in the same procedure as a gender-affirming surgical procedure. Final surgical pathology revealed a left-sided mixed germ cell tumor including teratoma, embryonal carcinoma, and yolk sac tumor. Postoperatively, her leuprolide was discontinued, and her estradiol was continued.

Conclusion

Nonsuppressed testosterone levels on GAFHT requires a straightforward approach to determine the etiology and therapeutic approach. An initial step is to review the degree of feminization achieved, medication-specific concerns, and assay-related reasons. Medication administration education, dosing adjustments, changes in estradiol preparations and routes of administration, and choice of testosterone assays may address the nonsuppressed testosterone levels. If these common reasons are nonrevealing, the next step would be to consider pituitary, adrenal, and gonadal sources of elevated testosterone. Gonadotropin levels and organ-specific testing and imaging can ultimately lead to the diagnosis.

Abbreviations

    Abbreviations

  • FGA

    functional pituitary gonadotroph adenoma

  • FSH

    follicle-stimulating hormone

  • GAFHT

    gender affirming feminizing hormonal therapy

  • GnRH

    gonadotropin-releasing hormone

  • LC-MS

    liquid chromatography–mass spectrometry

  • LH

  • SHBG

    sex hormone–binding globulin

  • TGD

    transgender and gender diverse

Additional Information

Disclosures: The authors have no financial disclosures. Hormone therapy for gender dysphoria/incongruence is off-label.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

1.

Hembree

WC

,

Cohen-Kettenis

PT

,

Gooren

L

, et al.

Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline

.

J Clin Endocrinol Metab.

2017

;

102

(

11

):

3869

-

3903

.

2.

Hamidi

O

,

Davidge-Pitts

CJ

.

Transfeminine hormone therapy

.

Endocrinol Metab Clin North Am.

2019

;

48

(

2

):

341

-

355

.

3.

Prior

JC

,

Vigna

YM

,

Watson

D

.

Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism

.

Arch Sex Behav.

1989

;

18

(

1

):

49

-

57

.

4.

Leinung

MC

,

Feustel

PJ

,

Joseph

J

.

Hormonal treatment of transgender women with oral estradiol

.

Transgend Health.

2018

;

3

(

1

):

74

-

81

.

5.

Liang

JJ

,

Jolly

D

,

Chan

KJ

,

Safer

JD

.

Testosterone levels achieved by medically treated transgender women in a United States endocrinology clinic cohort

.

Endocr Pract.

2018

;

24

(

2

):

135

-

142

.

6.

de Blok

CJM

,

Klaver

M

,

Wiepjes

CM

, et al.

Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study

.

J Clin Endocrinol Metab.

2018

;

103

(

2

):

532

-

538

.

7.

Deutsch

MB

,

Bhakri

V

,

Kubicek

K

.

Effects of cross-sex hormone treatment on transgender women and men

.

Obstet Gynecol.

2015

;

125

(

3

):

605

-

610

.

8.

Goldman

AL

,

Bhasin

S

,

Wu

FCW

,

Krishna

M

,

Matsumoto

AM

,

Jasuja

R

.

A reappraisal of testosterone's binding in circulation: physiological and clinical implications

.

Endocr Rev.

2017

;

38

(

4

):

302

-

324

.

9.

Mendel

CM

.

The free hormone hypothesis. Distinction from the free hormone transport hypothesis

.

J Androl.

1992

;

13

(

2

):

107

-

116

.

10.

Antonio

L

,

Wu

FC

,

O'Neill

TW

, et al. ;

European Male Ageing Study Study Group

.

Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone

.

J Clin Endocrinol Metab.

2016

;

101

(

7

):

2647

-

2657

.

11.

Bhasin

S

,

Brito

JP

,

Cunningham

GR

, et al.

Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline

.

J Clin Endocrinol Metab.

2018

;

103

(

5

):

1715

-

1744

.

12.

Trost

LW

,

Mulhall

JP

.

Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials

.

J Sex Med.

2016

;

13

(

7

):

1029

-

1046

.

14.

Rosner

W

.

Free estradiol and sex hormone-binding globulin

.

Steroids.

2015

;

99

(

Pt A

):

113

-

116

.

15.

Asscheman

H

,

T'Sjoen

G

,

Lemaire

A

, et al.

Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review

.

Andrologia.

2014

;

46

(

7

):

791

-

795

.

16.

Kuhl

H

.

Pharmacology of estrogens and progestogens: influence of different routes of administration

.

Climacteric.

2005

;

8

(

Suppl 1

):

3

-

63

.

17.

Doll

EE

,

Ian Gunsolus

B

,

Lamberton

N

,

Tangpricha

V

,

Lynne Sarvaideo

J

.

SUN-LB9 pharmacokinetics of sublingual versus oral estradiol in transgender women

.

J Endo Soc.

2020

;

4

.(Suppl 1):SUN-LB9. Published online May 8, 2020. doi:10.1210/jendso/bvaa046.2237

18.

Lycette

JL

,

Bland

LB

,

Garzotto

M

,

Beer

TM

.

Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?

Clin Genitourin Cancer.

2006

;

5

(

3

):

198

-

205

.

19.

Mamoojee

Y

,

Seal

LJ

,

Quinton

R

.

Transgender hormone therapy: understanding international variation in practice

.

Lancet Diabetes Endocrinol.

2017

;

5

(

4

):

243

-

246

.

20.

Gava

G

,

Cerpolini

S

,

Martelli

V

,

Battista

G

,

Seracchioli

R

,

Meriggiola

MC

.

Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness

.

Clin Endocrinol (Oxf).

2016

;

85

(

2

):

239

-

246

.

21.

Angus

L

,

Leemaqz

S

,

Ooi

O

, et al.

Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy

.

Endocr Connect.

2019

;

8

(

7

):

935

-

940

.

22.

Elshimy

G

,

Tran

K

,

Harman

SM

,

Correa

R

.

Unmasked testicular seminoma during use of hormonal transgender woman therapy: a hidden hCG-secreting tumor

.

J Endocr Soc.

2020

;

4

(

7

):

bvaa074

.

23.

Kvach

EJ

,

Hyer

JS

,

Carey

JC

,

Bowers

M

.

Testicular seminoma in a transgender woman: a case report

.

LGBT Health.

2019

;

6

(

1

):

40

-

42

.

24.

Wolf-Gould

CS

,

Wolf-Gould

CH

.

A Transgender woman with testicular cancer: a new twist on an old problem

.

LGBT Health.

2016

;

3

(

1

):

90

-

95

.

25.

Merke

DP

,

Auchus

RJ

.

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

.

N Engl J Med.

2020

;

383

(

13

):

1248

-

1261

.

26.

Sherlock

M

,

Scarsbrook

A

,

Abbas

A

, et al.

Adrenal incidentaloma

.

Endocr Rev.

2020

;

41

(

6

):775-820.

27.

Ntali

G

,

Capatina

C

,

Grossman

A

,

Karavitaki

N

.

Clinical review: functioning gonadotroph adenomas

.

J Clin Endocrinol Metab.

2014

;

99

(

12

):

4423

-

4433

.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Supplements To Increase Testosterone Ftm

Source: https://academic.oup.com/jes/article/5/9/bvab068/6231851

Share:

Sabtu, 11 Desember 2021

Will Creatine Boost Testosterone

Will Creatine Boost Testosterone

  • Review
  • Open Access
  • Published:

Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?

  • Darren G. Candow2,
  • Scott C. Forbes3,
  • Bruno Gualano4,
  • Andrew R. Jagim5,
  • Richard B. Kreider6,
  • Eric S. Rawson7,
  • Abbie E. Smith-Ryan8,
  • Trisha A. VanDusseldorp9,
  • Darryn S. Willoughby10 &
  • Tim N. Ziegenfuss11

Journal of the International Society of Sports Nutrition volume 18, Article number:13 (2021) Cite this article

  • 58k Accesses

  • 12 Citations

  • 304 Altmetric

  • Metrics details

Abstract

Supplementing with creatine is very popular amongst athletes and exercising individuals for improving muscle mass, performance and recovery. Accumulating evidence also suggests that creatine supplementation produces a variety of beneficial effects in older and patient populations. Furthermore, evidence-based research shows that creatine supplementation is relatively well tolerated, especially at recommended dosages (i.e. 3-5 g/day or 0.1 g/kg of body mass/day). Although there are over 500 peer-refereed publications involving creatine supplementation, it is somewhat surprising that questions regarding the efficacy and safety of creatine still remain. These include, but are not limited to: 1. Does creatine lead to water retention? 2. Is creatine an anabolic steroid? 3. Does creatine cause kidney damage/renal dysfunction? 4. Does creatine cause hair loss / baldness? 5. Does creatine lead to dehydration and muscle cramping? 6. Is creatine harmful for children and adolescents? 7. Does creatine increase fat mass? 8. Is a creatine 'loading-phase' required? 9. Is creatine beneficial for older adults? 10. Is creatine only useful for resistance / power type activities? 11. Is creatine only effective for males? 12. Are other forms of creatine similar or superior to monohydrate and is creatine stable in solutions/beverages? To answer these questions, an internationally renowned team of research experts was formed to perform an evidence-based scientific evaluation of the literature regarding creatine supplementation.

Introduction

Creatine (methylguanidine-acetic acid) is endogenously formed from reactions involving the amino acids arginine, glycine and methionine in the kidneys and liver [1]. Exogenously, creatine is primarily consumed from meat and/or as a dietary supplement. According to PubMed (archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine) there are over 500 peer-refereed publications involving various aspects of creatine supplementation. Based on the enormous popularity of creatine supplementation, the International Society of Sports Nutrition (ISSN) published an updated position stand in 2017 on the safety and efficacy of creatine supplementation in exercise, sport, and medicine [2]. This comprehensive paper provided an evidence-based review of the literature examining the effects of creatine supplementation on performance, recovery, injury prevention, exercise tolerance and rehabilitation, neuroprotection, aging, clinical and disease state populations, and pregnancy. Importantly, the safety profile of creatine was also reviewed. As of September 1, 2020, the paper has been viewed 179,000 times and cited 100 times (according to Web of Science). Furthermore, Altmetric data indicates that the paper has been mentioned in 19 news outlets, 4 blogs, 492 tweets, 54 Facebook pages, and been uploaded 69 times in video posts. Instagram stories and posts are not included as Altmetric data.

Despite the widespread outreach of the 2017 ISSN position stand paper [2], along with other evidence-based review/meta-analysis papers involving various aspects of creatine supplementation published after the 2015 Creatine in Health, Sport and Medicine Conference in Germany [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34], questions and misconceptions involving creatine supplementation still remain. These include, but are not limited to: 1. Does creatine supplementation lead to water retention? 2. Is creatine is an anabolic steroid? 3. Does creatine supplementation cause kidney damage / renal dysfunction? 4. Does creatine supplementation cause hair loss / baldness? 5. Does creatine supplementation lead to dehydration and muscle cramping? 6. Is creatine supplementation harmful for children and adolescents? 7. Does creatine supplementation increase body fat? 8. Is a creatine supplementation 'loading-phase' required? 9. Is creatine supplementation beneficial for older adults? 10. Is creatine supplementation only useful for resistance/power type activities? 11. Is creatine supplementation only effective for males? 12. Are other forms of creatine similar or superior to monohydrate? Is creatine stable in solutions/beverages? To address these questions, an internationally renowned team of research experts, who have collectively published over 200 peer-refereed articles involving creatine supplementation, was formed to perform an evidence-based scientific evaluation of the literature. Each question was answered by one researcher, chosen according to her/his expertise on the topic. Then, the final version of this manuscript was reviewed and approved by all authors, therefore reflecting the group opinion.

Does creatine lead to water retention?

The purported myth of creatine supplementation increasing body water (TBW) is likely due to early research which showed that creatine supplementation at 20 g/day for six days was associated with water retention [35]. It does appear that the most common adverse effect of creatine supplementation is water retention in the early stages (first several days) [36]. For example, studies have shown that three days of creatine supplementation increased TBW and extracellular body water (ECW) [37] and intracellular water (ICW) [38]. Unfortunately, based on these short-term responses, this notion that creatine increases water retention over the long-term has been widely accepted [39].

Creatine is an osmotically active substance. Thus, an increase in the body's creatine content could theoretically result in increased water retention. Creatine is taken up into muscle from circulation by a sodium-dependent creatine transporter [1]. Since the transport involves sodium, water will also be taken up into muscle to help maintain intracellular osmolality. However, considering the activity of the sodium-potassium pumps, it is not likely that intracellular sodium concentration is dramatically affected by creatine supplementation [39].

A number of exercise training studies (e.g., 5-10 weeks) incorporating creatine supplementation have shown no increases in total body water (TBW). For example, resistance-trained males who received creatine at a dose of 0.3 g/kg lean body mass/day for 7 days (approximately 20 g/day) followed by 4 weeks at 0.075 g/kg lean body mass/day for 28 days (approximately 5 g/day) experienced no significant change in ICW, ECW, or TBW [40]. Furthermore, resistance-trained males who consumed creatine supplementation (20 g/day for seven days followed by 5 g/day for 21 days) had no significant increase in ICW, ECW, or TBW [41]. Similarly, males and females ingesting creatine (0.03 g/kg/day for six weeks) experienced no significant increase in TBW [42]. Six weeks of creatine supplementation in non-resistance-trained males at a dosage of 0.3 g/kg lean body mass for five days followed by 0.075 g/kg lean body mass for 42 days produced no significant changes in TBW [43]. In contrast, when assessing TBW, ICW, and ECW content before and after 28 days of creatine supplementation in healthy males and females (n = 32), Powers et al. [44] showed that creatine supplementation was effective at increasing muscle creatine content which was associated with an increase in body mass and TBW but did not alter ICW or ECW volumes. In a recent study examining the effects of creatine supplementation combined with resistance exercise for 8 weeks, Ribeiro et al. [45] found a significant increase in TBW (7.0%) and ICW (9.2%) volume compared to placebo (TBW: 1.7%; ICW: 1.6%), with both groups similarly increasing ECW (CR: 1.2% vs. Placebo = 0.6%). Importantly, the ratio of skeletal muscle mass to ICW remained similar in both groups. It is important to highlight that the ICW is an important cellular signal for protein synthesis and thus drives an increase in muscle mass over time [46].

In summary, while there is some evidence to suggest that creatine supplementation increases water retention, primarily attributed to increases in intracellular volume, over the short term, there are several other studies suggesting it does not alter total body water (intra or extracellular) relative to muscle mass over longer periods of time. As a result, creatine supplementation may not lead to water retention.

Is creatine an anabolic steroid?

Anabolic steroids are a synthetic version of testosterone, an androgenic hormone which is also produced endogenously within both males and females, and is used in conjunction with resistance training with the intent of enhancing muscle mass and strength due to increases in muscle protein synthesis [47]. This increase in MPS is due to testosterone's ability to enter the muscle cell, bind with the intracellular androgen receptor, and increase the expression of various muscle-specific genes [48]. Creatine is converted to phosphocreatine (PCr), regulated by the enzyme creatine kinase (CK) in muscle and used to create intracellular adenosine triphosphate (ATP) production [1]. Creatine supplementation, however, can increase the capacity of ATP and energy produced during heavy anaerobically-related exercise, thereby possibly increasing muscle power, repetitions and exercise volume which can subsequently contribute to muscle performance and hypertrophy over the course of a training period [2].

While the physiological and performance outcomes of anabolic steroids and creatine can be similar, their mechanisms of action and legal categorization are not. Anabolic steroids are drugs, with a different chemical structure than creatine, and are Class C, Schedule III controlled substances regulated by the Food and Drug Administration (FDA) and subject to the regulatory control provisions of the Controlled Substances Act (CSA) set forth by the Drug Enforcement Association (DEA). Creatine, on the other hand, like many other dietary supplements fits well within the confines of The Dietary Supplement Health and Education Act of 1994 ("DSHEA"), which is a statute of United States Federal legislation which defines and regulates dietary supplements by the Federal Drug Administration (FDA) for Good Manufacturing Practices (GMP). It is illegal to possess and administer anabolic steroids without a physician's prescription. However, there are no legal ramifications for the possession or ingestion of creatine.

In summary, because creatine has a completely different chemical structure, it is not an anabolic steroid.

Does creatine cause kidney damage/renal dysfunction?

Questions and concerns involving creatine supplementation and kidney damage/renal dysfunction are common. In terms of pervasive misinformation in the sport nutrition arena, the notion that creatine supplementation leads to kidney damage/renal dysfunction is perhaps second only to the myth that protein supplementation and high habitual protein intake causes kidney damage. Today, after > 20 years of research which demonstrates no adverse effects from recommended dosages of creatine supplements on kidney health, unfortunately, this concern persists. While the origin is unknown, the connection between creatine supplementation and kidney damage/renal dysfunction could be traced back to two things: a poor understanding of creatine and creatinine metabolism and a case study published in 1998.

In skeletal muscle, both creatine and PCr are degraded non-enzymatically to creatinine, which is exported to the blood and excreted in the urine [1]. Healthy kidneys filter creatinine, which would otherwise increase in the blood. Therefore, blood creatinine levels can be used as a proxy marker of kidney function. However, the amount of creatinine in the blood is related to muscle mass (i.e. males have higher blood creatinine than females) and both dietary creatine and creatinine intake [35]. Both blood and urinary creatinine may be increased by ingestion of creatine supplementation and creatine containing foods, such as meat. Creatine is normally not present in urine, but can reach very high levels (>10 g/day) during creatine supplementation [49]. There appears to be an unsubstantiated perspective that if the kidneys are "forced" to excrete higher than normal levels of creatine or creatinine, some sort of kidney "overload" will take place, causing kidney damage and/or renal dysfunction. In reality, transient increases in blood or urinary creatine or creatinine due to creatine supplementation are unlikely to reflect a decrease in kidney function. Additionally, one must exercise caution when using blood creatinine and estimated creatinine clearance/glomerular filtration rate in individuals who consume high meat intake or supplement with creatine. In a review of creatine supplementation studies, Persky and Rawson [50] found no increase in serum creatinine in 12 studies, 8 studies showed an increase that remained within the normal range, and only 2 studies showed an increase above normal limits (although not different from the control group in one study).

In 1998, a case study of a young male with focal segmental glomerulosclerosis and relapsing nephrotic syndrome was reported [51]. The young male, who had kidney disease for 8 years and was treated with cyclosporine (i.e., immunosuppressant) for 5 years, had recently begun ingesting creatine supplementation (15 g/day for 7 days; followed by 2 g/day for 7 weeks). Based on increased blood levels of creatinine and subsequent estimate of calculated creatinine clearance, his kidney health was presumed to be deteriorating, although he was otherwise in good health. The patient was encouraged to discontinue creatine supplementation. At this time, it was already known that blood and urine creatinine levels can increase following ingestion of creatine containing food products, including creatine supplements [35]. This was ignored by the authors of this case study, as was the inclusion of two investigations which demonstrated that creatine supplementation did not negatively impact renal function [52, 53]. The dosage of creatine during the maintenance phase, which was also ignored, was only slightly higher than the daily creatine intake of a typical omnivore's dietary intake, or in terms of food, a large hamburger or steak per day (meat contains about 0.7 g of creatine / 6 oz. serving; see [54]). In response to this case study, two separate teams of experts in creatine metabolism wrote letters to the editor of Lancet [53, 55]. However, the notion that creatine supplementation leads to kidney damage and/or renal dysfunction gained traction and momentum.

Since this case study was reported in 1998, experimental and controlled research trials investigating the effects of creatine supplementation on kidney/renal function has substantially increased [50, 56,57,58]. Overall, in healthy individuals, there appears to be no adverse effects from consuming recommended doses of creatine supplements on kidney/renal function [50, 56,57,58]. Interestingly, Gualano et al. [58] reviewed a small number of case studies which reported renal dysfunction in individuals who were supplementing with creatine. Similar to the case report by Pritchard and Kalra [51], these additional case reports were confounded by medications, pre-existing kidney disease, concomitant supplement ingestion, inappropriate creatine dosages (e.g., 100 X recommended dose), and anabolic androgenic steroid use.

It is prudent to be cautious when ingesting any dietary supplement or medication. Survey data indicates that creatine supplementation usage ranges between 8-74% in athletes and other exercising individuals (reviewed in Rawson et al. [59]). Even with a low estimate of 8% of exercising individuals using creatine supplements, this indicates thousands of exposures across several decades. If the link between creatine supplementation and kidney health was valid, there would be an expected increase in kidney damage / renal dysfunction in low risk (i.e. young, physically fit, healthy) individuals since 1992 after Harris et al. published their seminal work [60]. After nearly 30 years of post-marketing surveillance, thousands of exposures, and multiple clinical trials, no such evidence exists.

In summary, experimental and controlled research indicates that creatine supplementation, when ingested at recommended dosages, does not result in kidney damage and/or renal dysfunction in healthy individuals.

Does creatine cause hair loss / baldness?

The vast majority of speculation regarding the relationship between creatine supplementation and hair loss/baldness stems from a single study by van der Merwe et al. [61] where college-aged male rugby players who supplemented with creatine (25 g/day for 7 days, followed by 5 g/day thereafter for an additional 14 days) experienced an increase in serum dihydrotestosterone (DHT) concentrations over time. Specifically, DHT increased by 56% after the seven-day loading period, and remained 40% above baseline values after the 14-day maintenance period. These results were statistically significant compared to when the subjects consumed a placebo (50 g of glucose per day for 7 days, followed by 30 g/day for 14 days thereafter). Given that changes in these hormones, particularly DHT, have been linked to some (but not all) occurrences of hair loss/baldness [62], the theory that creatine supplementation leads to hair loss / baldness gained some momentum and this potential link continues to be a common question / myth today. It is important to note that the results of van der Merwe et al. [61] have not been replicated, and that intense resistance exercise itself can cause increases in these androgenic hormones.

DHT is a metabolite of testosterone, formed when the enzyme 5-alpha-reductase converts free testosterone to DHT [63]. In males, DHT can bind to androgen receptors in susceptible hair follicles and cause them to shrink, ultimately leading to hair loss [64]. However, in the van der Merwe et al. [61] study, no increase in total testosterone was found in the 16 males who completed the study. Free testosterone was not measured. Moreover, the increase in DHT and the DHT: testosterone ratio remained well within normal clinical limits. Furthermore, baseline (prior to supplementation), DHT was 23% lower in the creatine group (0.98 nmol/L) compared to the placebo group (1.26 nmol/L). Thus the small increase in DHT in the creatine group (+ 0.55 nmol/L after 7 days of supplementation and + 0.40 nmol/L after 21 days of supplementation), in combination with a small decrease in the placebo DHT response (-0.17 nmol/L after 7 days of supplementation and -0.20 nmol/L after 21 days of supplementation) explains the "statistically significant" increase in DHT noted by van der Merwe et al. [61]. While it is possible that creatine supplementation upregulated 5-alpha-reductase activity in these males (potentially leading to increased formation of DHT), no study has reported hair loss/baldness in humans.

To date, 12 other studies have investigated the effects of creatine supplementation (i.e. doses ranging from 3-25 g/day for 6 days to 12 weeks) on testosterone. Two studies reported small, physiologically insignificant increases in total testosterone after six and seven days of supplementation [65, 66], while the remaining ten studies reported no change in testosterone concentrations. In five of these studies [67,68,69,70,71], free testosterone, which the body uses to produce DHT, was also measured and no increases were found.

In summary, the current body of evidence does not indicate that creatine supplementation increases total testosterone, free testosterone, DHT or causes hair loss/baldness.

Does creatine lead to dehydration and muscle cramping?

Speculation exists that creatine supplementation causes dehydration and muscle cramping [72, 73]. In the early 2000's, with limited data and based primarily on speculation, the American College of Sports Medicine (ACSM) recommended that individuals controlling their weight and exercising intensely or in hot environments should avoid the use of creatine supplementation [74]. The physiological rationale suggesting that creatine supplementation may cause dehydration and muscle cramping is based on the premise that creatine is an osmotically active substance found primarily in skeletal muscle and may alter whole-body fluid distribution by preferentially increasing intracellular water uptake and retention, particularly over the short-term [38, 75]. In situations of body water loss, such as severe sweating from exercise and/or increased environmental temperature, the bound intracellular fluid, in theory, may be detrimental to thermal regulation and lead to extracellular dehydration, electrolyte imbalance and muscle cramping or other heat-related musculoskeletal issues [44]. The initial loading phase of creatine supplementation (i.e. 20 g/day for 5-7 days) typically results in a 1-3 kg increase in body mass, mostly attributable to net body water retention [75, 76]. Some anecdotal evidence indicates that creatine users perceive supplementation to result in some adverse effects [77]. For example, in a survey involving 219 athletes, 90 participants reported using creatine with 34 of them (38%) reporting perceived negative effects such as cramping (27%) [77]. Similarly, in National Collegiate Athletic Association (NCAA) Division 1 baseball and football players (N=52) using creatine, 25% reported incidences of muscle cramping and 13.5% reported symptoms of dehydration. Importantly, these studies failed to control for the use of other supplements and the dosage of creatine ingested. Greenwood et al. [77] noted that 91% of participants exceeded the recommended creatine maintenance dose of 5 g/day. However, these self-report surveys are in contradiction to experimental and clinical evidence. Greenwood et al. [78] monitored injury rates in Division IA NCAA collegiate football players (N=72; age: 19.7 ± 1.0 yrs) where environmental conditions were hot (27.3 ± 10.90C) and humid (54.2 ± 9.7%). Participants chose to receive either creatine (n = 38: 0.3 g/kg/day for 5 days; followed by 0.03 g/kg/day for 115 days) or a sport drink placebo (n = 34) throughout the football season. Injuries treated by the athletic training staff were monitored. Creatine users had significantly less cramping (p = 0.021), heat illnesses and dehydration (p = 0.043), muscle tightness (p = 0.020), muscle strains (p = 0.021), and total injuries (p < 0.001) compared to non-users. Non-contact joint injuries, contact injuries, illnesses, missed practices due to injuries, and players lost for the season were not different between groups. In a clinical setting, haemodialysis patients (n = 10) who frequently reported muscle cramping were provided creatine (12 g) 5 minutes prior to haemodialysis [79]. Creatine supplementation reduced the frequency of symptomatic muscle cramping by 60% [79]. These beneficial effects from creatine may be explained by fluid distribution and electrolyte imbalances, as previously discussed.

In summary, experimental and clinical research does not validate the notion that creatine supplementation causes dehydration and muscle cramping.

Is creatine harmful for children and adolescents?

Concerns regarding the safety of creatine supplementation in children and adolescents (< 19 yrs) continues to be highly prevalent. The overwhelming majority of evidence in adult populations indicates that creatine supplementation, both short- and longer-term, is safe and generally well tolerated [2]. However, the question of whether or not this holds true for children and adolescents is relatively unclear. The physiological rationale supporting the potential ergogenic benefits of creatine supplementation in children and adolescents was first postulated by Unnithan and colleagues in 2001 [80]; which established a strong basis for future applications of creatine for younger athletes. More recently, in a comprehensive review examining the safety of creatine supplementation in adolescents, Jagim et al. [16] summarized several studies that examined the efficacy of creatine supplementation among various adolescent athlete populations and found no evidence of adverse effects. However, it is important to note that none of the performance-focused studies included in the Jagim et al. [16] review provided data examining specific markers of clinical health and whether or not they were impacted by the supplementation protocols.

From a clinical perspective, creatine supplementation has been found to potentially offer health benefits with minimal adverse effects in younger populations. Hayashi et al. [81] found improvements in pediatric patients with systemic lupus erythematosus and reported no adverse changes in laboratory parameters of hematology, kidney function, liver function or inflammatory markers after 12 weeks of creatine supplementation. Tarnopolsky et al. [82] reported significant improvements in fat-free mass and hand grip strength in 30 pediatric patients with Duchenne muscular dystrophy following 4 months of creatine supplementation. Importantly, the creatine supplementation protocol appeared to be well tolerated and did not adversely affect laboratory markers of kidney function, oxidative stress, and bone health [81,82,83]. In addition, Sakellaris et al. [83] reported significant improvements in traumatic brain injury-related outcomes in children and adolescents who received oral creatine supplementation (0.4 g/kg/day) for 6 months. These neurological benefits may have potential applications for young athletes participating in collision sports, which pose underlying risks of concussions or sub-concussive impacts. Further, several of these clinical trials implemented strict clinical surveillance measures, including continual monitoring of laboratory markers of kidney health, inflammation, and liver function; none of which were negatively impacted by the respective creatine supplementation interventions. These findings support the hypothesis of creatine supplementation likely being safe for children and adolescents. However, perhaps the strongest supporting evidence for the safety of creatine is the recent classification of creatine as generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA) in late 2020 (https://www.fda.gov/media/143525/download). Ultimately, this classification indicates that the currently available scientific data pertaining to the safety of creatine, is sufficient and has been agreed upon by a consensus of qualified experts, thereby determining creatine to be safe under the conditions of its intended use (https://www.fda.gov/media/143525/download). Even though infants and young children are excluded from GRAS, this would still apply to older children and adolescent populations.

The majority of dietary supplement survey data indicates that a relatively high percentage of youth and adolescent athletes are currently or have previously supplemented with creatine. For example, Kayton et al. [84] found that in a sample of 270 high school boys and girls, 21% of boys and 3% of girls reported supplementing with creatine. Furthermore, in a sample of elite Olympic level sample of young German athletes (14-18 yrs), 12% of those surveyed reported supplementing with creatine [85]. Therefore, these trends warrant additional research to determine with greater certainly whether creatine supplementation, both acute and longer-term, is safe for children and adolescents.

In summary, based on the limited evidence, creatine supplementation appears safe and potentially beneficial for children and adolescents.

Does creatine increase fat mass?

The theory that creatine supplementation increases fat mass is a concern amongst exercising individuals, possibly because some experience a gain in body mass from creatine supplementation. However, randomized controlled trials (one week to two years in duration) do not validate this claim. Acute creatine supplementation (7 days) had no effect on fat mass in young and older adults; however, fat-free mass was increased [86, 87]. Furthermore, three weeks of creatine supplementation had no effect on body composition in swimmers [88]. The addition of creatine to high-intensity interval training had no effect on body composition in recreationally active females [89]. In addition, the effects of creatine supplementation during resistance training overreaching had no effect on fat mass [70]. Moreover, in a group of healthy recreational male bodybuilders, 5 g/day of creatine consumed either pre- or post-training had no effect on fat mass [90]. In other short-terms studies lasting 6-8 weeks, there were no changes in fat mass from creatine supplementation. Becque et al. [91] found no changes in fat mass after six weeks of supplementation plus resistance training. In another 6-week investigation, no significant differences in fat mass or percentage body fat were observed after creatine supplementation [42]. Furthermore, creatine supplementation during an 8-week rugby union football season also had no effect on fat mass [92].

One might suggest that eight weeks or less of creatine supplementation is insufficient to arrive at a definitive conclusion regarding creatine's effect on fat mass. Nonetheless, there are several investigations that have used much longer treatment periods. For example, healthy resistance-trained males were randomly assigned in a double-blind fashion to supplement with creatine (i.e., 20 g/day for 1 week followed by 5 g/day for 11 weeks) or placebo [93]. Lean body mass and muscle fiber size increased; percent body fat and fat mass were unaffected over the 12-week training period [93]. In older males (~70 yrs), 12 weeks of creatine supplementation during resistance training had no effect (compared to placebo) on fat mass [94]. Furthermore, Gualano et al. assessed the effects of creatine supplementation (24 weeks), with and without resistance training, in older females. Results showed no effect from creatine on fat mass [95]. Candow et al. [96] examined the effects of creatine supplementation in older adults (50-71 years) over a 32-week treatment period. Study participants were randomized to supplement with creatine or placebo before or after resistance training (3 days per week). There was an increase over time for lean tissue and strength with a decrease in fat mass. From a clinical perspective, children with acute lymphoblastic leukemia who supplemented with creatine (0.1 g/kg/day) for two sequential periods of 16 weeks experienced a significant reduction in fat mass. In contrast, the children who did not consume creatine gained fat mass [97]. In two studies involving postmenopausal women, Lobo et al. [98] found no change in absolute or relative body fat from one-year of low-dose creatine supplementation. Furthermore, two years of creatine supplementation also had no effect on fat mass [99].

Recently, Forbes et al. [100] conducted a systematic review and meta-analysis on randomized controlled trials involving creatine supplementation in conjunction with resistance training on fat mass in older adults (≥ 50 yrs). Nineteen studies with a total of 609 participants were included. Participants supplementing with creatine had a greater reduction in body fat percentage. There was no significant difference in absolute fat mass loss; however, the creatine group lost ~0.5 kg more fat mass compared to those on placebo.

In summary, creatine supplementation does not increase fat mass across a variety of populations.

Is a creatine 'loading-phase' required?

Pioneering research in the early 1900's using animal models showed that creatine supplementation could augment creatine content by 70% [101, 102]. Decades later, Harris et al. [60] published a seminal paper which showed that 'loading' with creatine increased skeletal muscle creatine stores, as evaluated from muscle biopsies collected from the vastus lateralis in young, healthy human participants. This research sparked incredible interest in studying creatine supplementation strategies that would increase intramuscular creatine content, helping shape current recommendations.

Creatine 'loading' is defined as supplementing with oral creatine for 5–7 days with a dosage of 20–25 g/day, often divided into smaller doses throughout the day (e.g., four to five, 5 g servings/day). Creatine 'loading' may also be prescribed relative to body mass, for example, 0.3 g/kg/d for 5-7 days (i.e., 21 g/day for a 70 kg individual). The 'loading' phase of creatine supplementation is followed by a daily 'maintenance' phase often ranging from daily 3–5 g servings/day (Figure 1, side A). In addition to the seminal work of Harris et al. [60], several other investigations have demonstrated increased intramuscular creatine stores in humans from the creatine 'loading' phase [35, 103, 104]. A common misconception regarding creatine supplementation is that individuals must 'load' with creatine to increase intramuscular creatine stores and subsequently experience the purported ergogenic benefits of creatine supplementation. However, lower daily creatine supplementation dosing strategies (i.e., 3-5 g/day) are well established throughout the scientific literature for increasing intramuscular creatine stores leading to greater improvements in muscle mass, performance and recovery compared to placebo [2]. While effective, these non-loading creatine supplementation dosing strategies (Figure 1, side B) delay maximum intramuscular creatine storage. For example, in the classic 'loading' vs. daily 'maintenance' dose comparison study by Hultman et al. [35], creatine accumulation in muscle was similar (~ 20% increase) after participants consumed 3 g/day for 28 days or 20 g/day for 6 days [35]. Thus, it is currently recommended that individuals consume ~3-5 g/day of creatine for a minimum of 4 weeks in order to experience similar skeletal muscle saturation levels. Determination of which creatine supplementation strategy is preferred may depend on the goal of the individual. For instance, if an athlete is hoping to maximize the ergogenic potential of creatine supplementation in a very short period of time (< 30 days), adopting the creatine 'loading' strategy may be advised. However, if an athlete or exercising individual is planning to ingest creatine over an extended period of time (> 30 days), or if avoiding potential weight gain which can sometimes occur during creatine 'loading', the creatine 'maintenance' strategy would be a viable option. Athletes who are carrying out a creatine loading phase (i.e., 20 g/day) should emphasize the smaller dosing strategies (e.g. less than or equal to 10 gram servings) throughout the day, as dosages of greater than 10 grams may potentially lead to gastrointestinal distress (i.e., diarrhea) [105].

Fig. 1
figure1

Creatine supplementation strategies.

Full size image

In summary, accumulating evidence indicates that you do not have to 'load' creatine. Lower, daily dosages of creatine supplementation (i.e. 3-5 g/day) are effective for increasing intramuscular creatine stores, muscle accretion and muscle performance/recovery.

Is creatine beneficial for older adults?

There has been an increasing number of studies showing that creatine supplementation plays a therapeutic role in a variety of clinical conditions (see Gualano et al. [106] for a comprehensive review on this topic).

Perhaps one of the most promising conditions that could benefit from creatine supplementation is age-related sarcopenia. Sarcopenia is defined as a progressive and generalized skeletal muscle condition (i.e. decrease in muscle mass, strength, and functionality) that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality [107]. While resistance training is considered cornerstone in the treatment of sarcopenia [108], accumulating evidence indicates that creatine supplementation may enhance the anabolic environment produced by resistance training, subsequently mitigating indices of sarcopenia [9, 10, 19, 27].

Creatine supplementation can increase functionality (e.g., strength, activities of daily living, delay fatigue) and muscle mass in older adults [9, 10, 19, 87, 95, 109, 110]. However, the literature indicates that creatine alone (that is, without a concomitant resistance training program) is unlikely to result in substantial gains in muscle strength and functional performance [95, 111,112,113], although it does improve some parameters of muscle fatigue [114,115,116]. Likewise, most studies failed to show a beneficial effect of chronic creatine supplementation alone (≥ 30 days) on lean mass [98, 99, 113, 114]. For instance, we recently showed that creatine supplementation was not able to increase lean mass in postmenopausal women who supplemented with creatine (3 g/day) for 2 years, suggesting that creatine supplementation without exercise may be ineffective to prevent sarcopenia [99]. It is likely that increases in lean mass occasionally attributed to creatine supplementation in short-term studies (e.g., 7 days) are explained by increased body water, since creatine is osmotically active and it can sometimes induce water retention.

Conversely, substantial evidence indicates that creatine supplementation is capable of augmenting the hypertrophic response to resistance training in young adults [117], which is extended to older adults, as confirmed by three systematic reviews and meta-analyses [19, 118, 119]. The fact that creatine is more effective when combined with a training stimulus suggests that the main mechanistic action of creatine is its ability to enhance training volume and/or intensity, which may influence muscle protein kinetics, growth factors, satellite cells, inflammation and/or oxidative stress [9, 10, 19], ultimately resulting in greater skeletal muscle adaptations.

Regarding aging bone, emerging research over the past decade has shown some benefits from creatine supplementation. For example, healthy older males (> 50 yrs) who supplemented with creatine and performed whole-body resistance training for 10-12 weeks experienced an increase in upper limb bone mineral content [120] and a reduction in bone resorption compared to placebo [121]. More recently, Chilibeck et al. [122] showed that 52 weeks of creatine supplementation and supervised whole-body resistance training attenuated the rate of bone mineral loss in the hip region compared to placebo in postmenopausal females. However, a 2 year creatine supplementation protocol was infective for improving bone mass or bone geometry in post-menopausal women, again suggesting that creatine should be combined with resistance-type exercise to produce beneficial bone adaptations [99].

From a clinical and healthy aging perspective, it is recommended that creatine supplementation be combined with resistance training to produce the greatest adaptations in older adults. Future clinical trials involving frail populations with long-term follow-up(s) and larger samples are needed. The therapeutic potential of creatine supplementation for cachexia, myopathies, post-surgery rehabilitation, bed rest, other muscle/bone wasting condition/diseases and brain health warrants further investigation.

In summary, there is growing body of evidence showing that creatine supplementation, particularly when combined with exercise, provides musculoskeletal and performance benefits in older adults.

Is creatine only useful for resistance / power type activities?

Although creatine supplementation has been theorized to primarily benefit athletes involved in high-intensity intermittent resistance/power type activities, there is a growing body of evidence suggesting that creatine supplementation may also provide beneficial effects for other activities. For example, creatine supplementation with carbohydrate [123] or carbohydrate and protein [124] has been reported to promote greater muscle glycogen storage than carbohydrate supplementation alone. Since glycogen replenishment is important for promoting recovery and preventing overtraining during intensified training periods [2, 125], creatine supplementation may help athletes who deplete large amounts of glycogen during training and/or performance (i.e., sporting events) to maintain optimal glycogen levels. Second, there is evidence that creatine supplementation may reduce muscle damage and/or enhance recovery from intense exercise. For example, Cooke and colleagues [126] reported that creatine supplementation during recovery from exercise-induced muscle damage promoted less muscle enzyme efflux and better maintenance of isokinetic muscle performance. Moreover, there is evidence that individuals supplementing their diet with creatine experienced less muscle damage, inflammation, and muscle soreness in response to running 30-km [127] as well as during 4-weeks of intensified training [70]. Consequently, creatine supplementation may help athletes recover from intense exercise and/or tolerate intensified periods of training to a greater degree. Third, there is evidence that athletes who supplement with creatine during training experience fewer musculoskeletal injuries, accelerated recovery time from injury [78, 128] and less muscle atrophy after immobilization [129, 130]. Whether this is due to a greater resistance to injury and/or ability to recover from injury remains unclear. Fourth, creatine supplementation (with or without glycerol) has been reported to help athletes hyper-hydrate and thereby enhance tolerance to exercise in the heat [28, 37, 131,132,133,134,135,136,137,138,139,140,141,142,143,144,145]. Therefore, creatine supplementation may reduce the risk of heat related-illness when athletes train and/or compete in hot and humid environments [72, 146]. Finally, there is evidence from animal models that creatine supplementation is neuroprotective [147,148,149] and can reduce the severity of spinal cord injury [150, 151], cerebral ischemia [152,153,154,155], and concussion/traumatic brain injury [2, 7, 12, 22, 32, 33, 156]. This evidence was so compelling that the International Society of Sports Nutrition recommended that athletes engaged in sports that have a potential for concussion and/or spinal cord injury take creatine for its neuroprotective effects [2]. Thus, there are a number of reasons beyond the ergogenic benefit that all types of athletes may benefit.

In summary, there is a variety of athletic events, not just resistance/power activities, which may benefit from creatine supplementation.

Is creatine only effective for males?

Creatine kinetics may vary between healthy males and females [157]. Females may have higher intramuscular creatine concentrations [158] possibly due to lower skeletal muscle mass [159]. Potentially, the higher resting intramuscular creatine concentration in females (based on the upper limit of intramuscular creatine storage) may help explain some research showing diminished responsiveness and/or performance effects on females [160, 161].

As a result of hormone-driven changes in endogenous creatine synthesis, creatine transport, and creatine kinase (CK) kinetics, creatine bioavailability throughout various stages of female reproduction is altered, highlighting the potential positive implications for creatine supplementation in females [29]. The implications of hormone-related changes in creatine kinetics has been largely overlooked in performance-based studies [29]. Specifically, creatine supplementation may be of particular importance during menses, pregnancy, post-partum, perimenopause and postmenopause. Creatine kinase, as well as enzymes associated with creatine synthesis, are influenced by estrogen and progesterone [1]. Creatine kinase levels are significantly elevated during menstruation [162], with CK levels decreasing throughout the menstrual cycle, pregnancy, and with age. The lowest range of CK values have been reported during early pregnancy (20 weeks or less), equating to about half the concentration found at peak levels (teenage girls) [162, 163].

Maternal creatine supplementation during pregnancy in pre-clinical animal studies have demonstrated a protective effect against fetal death and organ damage associated with intrapartum hypoxia [164, 165]. Reduced creatine levels in late pregnancy have also been associated with low fetal growth [165]. There is additional data that metabolic demand from the placenta during gestation further lowers the creatine pool of the mother [166], which may be associated with low birth weight and pre-term birth. Creatine supplementation during pregnancy has been shown to enhance neuronal cell uptake of creatine and support mitochondrial integrity in animal offspring, thereby reducing brain injury induced by intrapartum asphyxia [167, 168]. Although there are no human studies evaluating the effects of creatine supplementation during pregnancy, creatine could provide a safe, low-cost nutritional interventional for reducing intra- and post-partum complications associated with cellular energy depletion [169]. This may be more important if the female is vegetarian, or unable to consume meat due to nausea or taste preferences (i.e. meat contains about 0.7 g of creatine/6 oz serving [54];).

Females have been reported to have lower levels of creatine in the brain (frontal lobe) [170]. Increasing creatine concentrations in the brain as a result of supplementation, particularly in females, may support the reported benefits of reducing symptoms of depression [171, 172] and ameliorating the effects of traumatic brain injury [12, 22]. Depression is about 2 times higher among females throughout the reproductive years [173] and accelerates around pubertal hormonal changes [174]. Altered brain bioenergetics and mitochondrial dysfunction have been linked with depression, particularly as it relates to CK, ATP, and inorganic phosphate (Pi). Creatine supplementation has been shown to significantly augment cerebral PCr and Pi [175], particularly in females. The increase in cerebral PCr from 10 g of creatine supplementation was reported to be inversely related to symptoms of depression in adolescent females resistant to selective serotonin reuptake inhibitors [171] It appears that creatine supplementation may be effective for supporting creatine kinetics, mood, and pregnancy/fetal outcomes.

There is a small body of research that has investigated the effects of creatine supplementation in younger females. For example, Vandenberghe et al. [176] showed that creatine supplementation (20 g/day for 4 days followed by 5 g/day thereafter) during 10 weeks of resistance training significantly increased intramuscular concentrations, muscle mass and strength compared to placebo in females (19-22 yrs). In elite female soccer players (22 ± 5 yrs), creatine supplementation (20 g/day for 6 days) improved sprint and agility performance compared to placebo [177]. Hamilton et al. [178] showed that creatine supplementation (25 g for 7 days) augmented upper-body exercise capacity in strength-trained females (21-33 yrs) compared to placebo (19-29 yrs). Furthermore, in college-aged females (20 yrs), creatine supplementation (0.5 g/kg of fat-free mass for 5 days) improved knee extension muscle performance compared to placebo [179]. In contrast, not all data show improved performance in females [89, 160, 161]. Additionally, Smith-Ryan et al. [180] reported no significant effects of creatine loading on neuromuscular properties of fatigue in young adult females. It is important to evaluate the benefit to risk ratio; as noted elsewhere in this document, there are minimal risks associated with creatine supplementation, particularly when it is evaluated against the potential benefits in females.

Accumulating research over the past decade in postmenopausal females demonstrates that creatine supplementation during a resistance training program can improve muscle mass, upper- and lower-body strength, and tasks of functionality (30-s chair stand, lying prone-to-stand test, arm curl test) (for detailed review see Candow et al. [9]). Creatine supplementation appears to be a viable option for post-menopausal females to improve muscle quality and performance. In addition to its beneficial effects on aging muscle, creatine supplementation may also have favorable effects on bone in postmenopausal females, if combined with resistance training. For example, postmenopausal females who supplemented daily with 0.1 g/kg/day of creatine during 52-weeks of supervised whole-body resistance training experienced an attenuation in the rate of bone mineral loss at the femoral neck (hip), compared to females on placebo during training [122]. Furthermore, 5 g/day of creatine supplementation during 12 weeks of resistance training in postmenopausal females resulted in a significant increase in muscle mass and upper- and lower-body strength, compared to placebo [181]. However, even without the stimulus of resistance training, there is some evidence that creatine supplementation can still be beneficial. For example, in aging females (n=10; 67 ± 6 yrs), acute creatine supplementation (0.3 g/kg/day for 7 days) significantly improved lower-extremity physical performance (sit-to-stand test) [110], and fat-free mass and upper- and lower-body strength compared to placebo [86].

In summary, there is accumulating evidence that creatine supplementation has the potential to be a multifactorial therapeutic intervention across the lifespan in females, with little to no side effects.

Are other forms of creatine similar or superior to monohydrate and is creatine stable in solutions/beverages?

Creatine monohydrate powder has been the most extensively studied and commonly used form of creatine in dietary supplements since the early 1990s [2, 125]. Creatine monohydrate was used in early studies to assess bioavailability, determine proper dosages, and assess the impact of oral ingestion of creatine on blood creatine and intramuscular creatine stores [35, 60, 182]. These studies indicated that orally ingested creatine monohydrate (e.g., 3–5 g/day) increases blood concentrations of creatine for 3-4 hours after ingestion thereby facilitating the uptake of creatine into tissue through diffusion and creatine transporters [1, 183, 184]. Additionally, it is well established that ~99% of orally ingested creatine monohydrate is either taken up by tissue or excreted in the urine as creatine through normal digestion [60, 185, 186]. Short-term loading with creatine monohydrate (e.g., consuming 5 g, 4 times daily for 5-7 days) has been reported to increase intramuscular creatine stores by 20–40% and exercise performance capacity by 5–10% [2, 125]. Creatine monohydrate supplementation during training (e.g., 5–25 g/day for 4–12 weeks) has been reported to promoted gains in muscle mass, strength, and exercise capacity [2, 125]. Despite the known efficacy, safety, and low cost of creatine monohydrate; a number of different forms of creatine have been marketed as more effective with fewer anecdotally reported adverse effects [187]. These marketing efforts have fueled speculation that creatine monohydrate is not the most effective or safest form of creatine to consume. This notion is clearly refuted by understanding the well-known physio-chemical properties of creatine monohydrate, as well as current creatine supplementation literature.

A number of different forms of creatine (e.g., creatine salts, creatine complexed with other nutrients, creatine dipeptides, etc.) have been marketed as more effective sources of creatine than creatine monohydrate [187]. However, there are no peer-reviewed published papers showing that the ingestion of equal amounts of creatine salts [188,189,190,191] or other forms of creatine like effervescent creatine [128], creatine ethyl ester [43, 192, 193], buffered creatine [41], creatine nitrate [194, 195], creatine dipeptides, or the micro amounts of creatine contained in creatine serum [196] and beverages (e.g., 25–50 mg) increases creatine storage in muscle to a greater degree than creatine monohydrate [187]. In fact, most studies show that ingestion of these other forms have less physiological impact than creatine monohydrate on intramuscular creatine stores and/or performance and that any performance differences were more related to other nutrients that creatine is bound to or co-ingested with in supplement formulations. This makes sense given that these other forms contain less creatine per gram than creatine monohydrate and that 99% of ingested creatine monohydrate is absorbed into the blood, then taken up into muscle, or excreted in urine [187].

Creatine monohydrate crystallizes from water as monoclinic prisms that hold one molecule of water of crystallization per molecule of creatine [187]. Subsequent drying of creatine monohydrate at about 100°C removes the water of crystallization yielding anhydrous creatine (100% creatine) [187]. Creatine is considered a weak base (pKb 11.02 at 25°C) that can only form salts with strong acids (i.e., pKa < 3.98). Creatine can also serve as a complexing agent with other compounds via ionic binding. Creatine monohydrate powder contains the highest percentage of creatine (87.9%) other than creatine anhydrous [187]. Creatine monohydrate manufactured in Germany involves adding acetic acid to sodium sarconsinate, heating, adding cyanamide, cooling to promote crystallization, separation and filtration, and drying has been reported to produce 99.9% pure creatine monohydrate with no contaminants. Meanwhile, other sources of creatine monohydrate that have different starting materials (e.g., sarcosinates and O-alkylisourea, sarcosinates and S-alkylisothiourea) and methods of creatine synthesis, particularly from sources produced in China, have been found to contain up to 5.4% dicyandiamide, 0.09% dihydrotriazine, 1.3% creatinine, dimethyl sulphate, thiourea, and/or higher concentrations of heavy metals like mercury and lead due to use of different chemical precursors, poorly controlled synthesis processes, and/or inadequate filtration methods that more readily produce these contaminants [197]. While the effects of ingesting these compounds on health are unknown, contamination with dihydrotriazine has been suggested to be of greatest concern since it is structurally related to carcinogenic compounds [197]. For this reason, German sourced creatine monohydrate has been primarily used in research to establish safety and efficacy and is therefore the recommended source of creatine monohydrate to use in dietary supplements [2, 187].

Creatine monohydrate powder is very stable showing no signs of degradation into creatinine over years, even at elevated storage temperatures [187]. However, creatine is not stable in solution due to intramolecular cyclization that converts creatine to creatinine especially at higher temperatures and lower pH [187, 198,199,200]. The degradation of creatine can be reduced or halted by lowering the pH under 2.5 or increasing the pH above 12.1 [187]. This is the reason that less than 1% of creatine monohydrate is degraded to creatinine during the digestive process and creatine is taken up by tissue or excreted in urine after ingestion [60, 185,186,187]. Moreover, since creatine is an ampholytic amino acid, it is not very soluble in water (e.g., creatine monohydrate dissolves at 14 g/L at 20°C with a neutral pH of 7) [187]. Mixing creatine in higher temperature solution increase solubility, which is the reason why initial studies administered creatine in hot tea [35, 60, 103, 104, 123, 182] but the solubility has no influence on tissue uptake [187]. The lack of solubility and stability of creatine in solution is the reason that creatine is primarily marketed in powder form and efforts to develop stable beverages containing physiologically effective doses of creatine (e.g., 3–5 g per serving) have been unsuccessful.

In summary, while some forms of creatine may be more soluble than creatine monohydrate when mixed in fluid, evidence-based research clearly shows creatine monohydrate to be the optimal choice.

Conclusions

Based on our evidence-based scientific evaluation of the literature, we conclude that:

  1. (1).

    Creatine supplementation does not always lead to water retention.

  2. (2).

    Creatine is not an anabolic steroid.

  3. (3).

    Creatine supplementation, when ingested at recommended dosages, does not result in kidney damage and/or renal dysfunction in healthy individuals.

  4. (4).

    The majority of available evidence does not support a link between creatine supplementation and hair loss / baldness.

  5. (5).

    Creatine supplementation does not cause dehydration or muscle cramping.

  6. (6).

    Creatine supplementation appears to be generally safe and potentially beneficial for children and adolescents.

  7. (7).

    Creatine supplementation does not increase fat mass.

  8. (8).

    Smaller, daily dosages of creatine supplementation (3-5 g or 0.1 g/kg of body mass) are effective. Therefore, a creatine 'loading' phase is not required.

  9. (9).

    Creatine supplementation and resistance training produces the vast majority of musculoskeletal and performance benefits in older adults. Creatine supplementation alone can provide some muscle and performance benefits for older adults.

  10. (10).

    Creatine supplementation can be beneficial for a variety of athletic and sporting activities.

  11. (11).

    Creatine supplementation provides a variety of benefits for females across their lifespan.

  12. (12).

    Other forms of creatine are not superior to creatine monohydrate.

Availability of data and materials

Not applicable.

Abbreviations

ACSM:

American College of Sports Medicine

ATP:

Adenosine triphosphate

C:

Celsius

CK:

Creatine kinase

CSA:

Controlled substances act

DEA:

Drug enforcement association

DHT:

Dihydrotestosterone

DSHEA:

Dietary Supplement Health and Education Act

ECW:

Extracellular water

FDA:

Food and Drug Administration

G:

Grams

GMP:

Good Manufacturing Practices

ICW:

Intracellular water

ISSN:

International Society of Sports Nutrition

Kg:

Kilogram

Km:

Kilometer

L:

Liter

MPS:

Muscle protein synthesis

NCAA:

National Collegiate Athletic Association

Nmol:

Nanomole

Oz:

Ounce

PCr:

Phosphocreatine

pH:

Potential hydrogen

s:

Seconds

pKa:

Acid dissociation constant

Pi :

Inorganic phosphate

TBW:

Total body water

Yrs:

Years of age

References

  1. 1.

    Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000;80:1107–213.

    CAS  PubMed  Article  Google Scholar

  2. 2.

    Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J. Int. Soc. Sports Nutr. 2017;14:18-z eCollection 2017.

    Article  CAS  Google Scholar

  3. 3.

    Bongiovanni T, Genovesi F, Nemmer M, Carling C, Alberti G, Howatson G. Nutritional interventions for reducing the signs and symptoms of exercise-induced muscle damage and accelerate recovery in athletes: current knowledge, practical application and future perspectives. Eur. J. Appl. Physiol. 2020;120:1965–96.

    PubMed  Article  Google Scholar

  4. 4.

    de Guingand DL, Palmer KR, Snow RJ, Davies-Tuck ML, Ellery SJ. Risk of Adverse Outcomes in Females Taking Oral Creatine Monohydrate: A Systematic Review and Meta-Analysis. Nutrients. 2020;12. https://doi.org/10.3390/nu12061780.

  5. 5.

    Kaviani M, Shaw K, Chilibeck PD. Benefits of Creatine Supplementation for Vegetarians Compared to Omnivorous Athletes: A Systematic Review. Int. J. Environ. Res. Public. Health. 2020:17. https://doi.org/10.3390/ijerph17093041.

  6. 6.

    Vega J, Huidobro EJP. Effects of creatine supplementation on renal function. Rev. Med. Chil. 2019;147:628–33.

    PubMed  Article  Google Scholar

  7. 7.

    Dolan E, Gualano B, Rawson ES. Beyond muscle: the effects of creatine supplementation on brain creatine, cognitive processing, and traumatic brain injury. Eur. J. Sport. Sci. 2019;19:1–14.

    PubMed  Article  Google Scholar

  8. 8.

    Dolan E, Artioli GG, Pereira RMR, Gualano B. Muscular Atrophy and Sarcopenia in the Elderly: Is There a Role for Creatine Supplementation? Biomolecules. 2019;9. https://doi.org/10.3390/biom9110642.

  9. 9.

    Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB. Effectiveness of Creatine Supplementation on Aging Muscle and Bone: Focus on Falls Prevention and Inflammation. J. Clin. Med. 2019:8. https://doi.org/10.3390/jcm8040488.

  10. 10.

    Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB. Variables Influencing the Effectiveness of Creatine Supplementation as a Therapeutic Intervention for Sarcopenia. Front. Nutr. 2019;6:124.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  11. 11.

    Marques EP, Wyse ATS. Creatine as a Neuroprotector: an Actor that Can Play Many Parts. Neurotox Res. 2019;36:411–23.

    PubMed  Article  Google Scholar

  12. 12.

    Balestrino M, Adriano E. Beyond sports: Efficacy and safety of creatine supplementation in pathological or paraphysiological conditions of brain and muscle. Med. Res. Rev. 2019;39:2427–59.

    CAS  PubMed  Article  Google Scholar

  13. 13.

    Sumien N, Shetty RA, Gonzales EB. Creatine, Creatine Kinase, and Aging. Subcell. Biochem. 2018;90:145–68.

    CAS  PubMed  Article  Google Scholar

  14. 14.

    Fairman CM, Kendall KL, Hart NH, Taaffe DR, Galvao DA, Newton RU. The potential therapeutic effects of creatine supplementation on body composition and muscle function in cancer. Crit. Rev. Oncol. Hematol. 2019;133:46–57.

    CAS  PubMed  Article  Google Scholar

  15. 15.

    Valenzuela PL, Morales JS, Emanuele E, Pareja-Galeano H, Lucia A. Supplements with purported effects on muscle mass and strength. Eur. J. Nutr. 2019;58:2983–3008.

    CAS  PubMed  Article  Google Scholar

  16. 16.

    Jagim AR, Stecker RA, Harty PS, Erickson JL, Kerksick CM. Safety of Creatine Supplementation in Active Adolescents and Youth: A Brief Review. Front. Nutr. 2018;5:115.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  17. 17.

    Davani-Davari D, Karimzadeh I, Sagheb MM, Khalili H. The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders. J. Ren. Nutr. 2019;29:221–34.

    CAS  PubMed  Article  Google Scholar

  18. 18.

    Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, Bischoff-Ferrari H, Bruyere O, Cesari M, Dawson-Hughes B, Fielding RA, Kaufman JM, Landi F, Malafarina V, Rolland Y, van Loon LJ, Vellas B, Visser M, Cooper C. ESCEO working group Does nutrition play a role in the prevention and management of sarcopenia? Clin. Nutr. 2018;37:1121–32.

    CAS  PubMed  Article  Google Scholar

  19. 19.

    Chilibeck PD, Kaviani M, Candow DG, Zello GA. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J. Sports Med. 2017;8:213–26.

    PubMed  PubMed Central  Article  Google Scholar

  20. 20.

    Butts J, Jacobs B, Silvis M. Creatine Use in Sports. Sports Health. 2018;10:31–4.

    PubMed  Article  Google Scholar

  21. 21.

    Farshidfar F, Pinder MA, Myrie SB. Creatine Supplementation and Skeletal Muscle Metabolism for Building Muscle Mass- Review of the Potential Mechanisms of Action. Curr. Protein Pept. Sci. 2017;18:1273–87.

    CAS  PubMed  Article  Google Scholar

  22. 22.

    Ainsley Dean PJ, Arikan G, Opitz B, Sterr A. Potential for use of creatine supplementation following mild traumatic brain injury. Concussion. 2017;2 CNC34-0016. eCollection 2017 Jun.

  23. 23.

    Andres RH, Wallimann T, Widmer HR. Creatine supplementation improves neural progenitor cell survival in Huntington's disease. Brain Circ. 2016;2:133–7.

    PubMed  PubMed Central  Article  Google Scholar

  24. 24.

    Andres S, Ziegenhagen R, Trefflich I, Pevny S, Schultrich K, Braun H, Schanzer W, Hirsch-Ernst KI, Schafer B, Lampen A. Creatine and creatine forms intended for sports nutrition. Mol. Nutr. Food Res. 2017;61. https://doi.org/10.1002/mnfr.201600772 Epub 2017 Mar 30.

  25. 25.

    Lanhers C, Pereira B, Naughton G, Trousselard M, Lesage FX, Dutheil F. Creatine Supplementation and Upper Limb Strength Performance: A Systematic Review and Meta-Analysis. Sports Med. 2017;47:163–73.

    PubMed  Article  Google Scholar

  26. 26.

    Pinto CL, Botelho PB, Pimentel GD, Campos-Ferraz PL, Mota JF. Creatine supplementation and glycemic control: a systematic review. Amino Acids. 2016;48:2103–29.

    CAS  PubMed  Article  Google Scholar

  27. 27.

    Gualano B, Rawson ES, Candow DG, Chilibeck PD. Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain. Amino Acids. 2016;48:1793–805.

    CAS  PubMed  Article  Google Scholar

  28. 28.

    Twycross-Lewis R, Kilduff LP, Wang G, Pitsiladis YP. The effects of creatine supplementation on thermoregulation and physical (cognitive) performance: a review and future prospects. Amino Acids. 2016;48:1843–55.

    CAS  PubMed  Article  Google Scholar

  29. 29.

    Ellery SJ, Walker DW, Dickinson H. Creatine for women: a review of the relationship between creatine and the reproductive cycle and female-specific benefits of creatine therapy. Amino Acids. 2016;48:1807–17.

    CAS  PubMed  Article  Google Scholar

  30. 30.

    Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids. 2016;48:1785–91.

    CAS  PubMed  Article  Google Scholar

  31. 31.

    Deminice R, de Castro GS, Brosnan ME, Brosnan JT. Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings. Amino Acids. 2016;48:1983–91.

    CAS  PubMed  Article  Google Scholar

  32. 32.

    Balestrino M, Sarocchi M, Adriano E, Spallarossa P. Potential of creatine or phosphocreatine supplementation in cerebrovascular disease and in ischemic heart disease. Amino Acids. 1955-1967;2016:48.

    Google Scholar

  33. 33.

    Freire Royes LF, Cassol G. The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury. Mini Rev. Med. Chem. 2016;16:29–39.

    CAS  PubMed  Article  Google Scholar

  34. 34.

    Riesberg LA, Weed SA, McDonald TL, Eckerson JM, Drescher KM. Beyond muscles: The untapped potential of creatine. Int. Immunopharmacol. 2016;37:31–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  35. 35.

    Hultman, E.; Soderlund, K.; Timmons, J. A.; Cederblad, G.; Greenhaff, P. L. Muscle creatine loading in men. J. Appl. Physiol. (1985) 1996, 81, 232-237.

  36. 36.

    Hall M, Trojian TH. Creatine supplementation. Curr. Sports Med. Rep. 2013;12:240–4.

    PubMed  Article  Google Scholar

  37. 37.

    Rosene JM, Matthews TD, Mcbride KJ, Galla A, Haun M, Mcdonald K, Gagne N, Lea J, Kasen J, Farias C. The effects of creatine supplementation on thermoregulation and isokinetic muscular performance following acute (3-day) supplementation. J. Sports Med. Phys. Fitness. 2015;55:1488–96.

    CAS  PubMed  Google Scholar

  38. 38.

    Ziegenfuss T, Lowery LM, Lemon P. Acute fluid volume changes in men during three days of creatine supplementation. Journal of Exercise Physiology Online. 1998;1:1.

    Google Scholar

  39. 39.

    Francaux M, Poortmans JR. Side effects of creatine supplementation in athletes. Int. J. Sports Physiol. Perform. 2006;1:311–23.

    PubMed  Article  Google Scholar

  40. 40.

    Andre TL, Gann JJ, McKinley-Barnard SK, Willoughby DS. Effects of five weeks of resistance training and relatively-dosed creatine monohydrate supplementation on body composition and muscle strength and whole-body creatine metabolism in resistance-trained males. Int J Kinesiol Sports Sci. 2016;4:28–35.

    Google Scholar

  41. 41.

    Jagim AR, Oliver JM, Sanchez A, Galvan E, Fluckey J, Riechman S, Greenwood M, Kelly K, Meininger C, Rasmussen C, Kreider RB. A buffered form of creatine does not promote greater changes in muscle creatine content, body composition, or training adaptations than creatine monohydrate. J. Int. Soc. Sports Nutr. 2012;9:43–3.

  42. 42.

    Rawson ES, Stec MJ, Frederickson SJ, Miles MP. Low-dose creatine supplementation enhances fatigue resistance in the absence of weight gain. Nutrition. 2011;27:451–5.

    CAS  PubMed  Article  Google Scholar

  43. 43.

    Spillane M, Schoch R, Cooke M, Harvey T, Greenwood M, Kreider R, Willoughby DS. The effects of creatine ethyl ester supplementation combined with heavy resistance training on body composition, muscle performance, and serum and muscle creatine levels. J. Int. Soc. Sports Nutr. 2009;6:6–6.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  44. 44.

    Powers ME, Arnold BL, Weltman AL, Perrin DH, Mistry D, Kahler DM, Kraemer W, Volek J. Creatine Supplementation Increases Total Body Water Without Altering Fluid Distribution. J. Athl Train. 2003;38:44–50.

    PubMed  PubMed Central  Google Scholar

  45. 45.

    Ribeiro AS, Avelar A, Kassiano W, Nunes JP, Schoenfeld BJ, Aguiar AF, Trindade MCC, Silva AM, Sardinha LB, Cyrino ES. Creatine Supplementation Does Not Influence the Ratio Between Intracellular Water and Skeletal Muscle Mass in Resistance-Trained Men. Int. J. Sport Nutr. Exerc. Metab. 2020:1–7.

  46. 46.

    Safdar A, Yardley NJ, Snow R, Melov S, Tarnopolsky MA. Global and targeted gene expression and protein content in skeletal muscle of young men following short-term creatine monohydrate supplementation. Physiol. Genomics. 2008;32:219–28.

    CAS  PubMed  Article  Google Scholar

  47. 47.

    Kersey RD, Elliot DL, Goldberg L, Kanayama G, Leone JE, Pavlovich M, Pope HG. National Athletic Trainers' Association National Athletic Trainers' Association position statement: anabolic-androgenic steroids. J. Athl Train. 2012;47:567–88.

    PubMed  PubMed Central  Article  Google Scholar

  48. 48.

    Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin. Biochem. Rev. 2016;37:3–15.

    PubMed  PubMed Central  Google Scholar

  49. 49.

    Rawson ES, Clarkson PM, Price TB, Miles MP. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. Acta Physiol. Scand. 2002;174:57–65.

    CAS  PubMed  Article  Google Scholar

  50. 50.

    Persky AM, Rawson ES. Safety of creatine supplementation. Subcell. Biochem. 2007;46:275–89.

    PubMed  Article  Google Scholar

  51. 51.

    Pritchard NR, Kalra PA. Renal dysfunction accompanying oral creatine supplements. Lancet. 1998;351:1252–3.

    CAS  PubMed  Article  Google Scholar

  52. 52.

    Poortmans JR, Auquier H, Renaut V, Durussel A, Saugy M, Brisson GR. Effect of short-term creatine supplementation on renal responses in men. Eur. J. Appl. Physiol. Occup. Physiol. 1997;76:566–7.

    CAS  PubMed  Article  Google Scholar

  53. 53.

    Greenhaff P. Renal dysfunction accompanying oral creatine supplements. Lancet. 1998;352:233–4.

    CAS  PubMed  Article  Google Scholar

  54. 54.

    Rawson ES. The safety and efficacy of creatine monohydrate supplementation: What we have learned from the past 25 years of research. Gatorade Sports Science Exchange. 2018;29:1–6.

    Google Scholar

  55. 55.

    Poortmans JR, Francaux M. Renal dysfunction accompanying oral creatine supplements. Lancet. 1998;352:234–3.

    CAS  PubMed  Article  Google Scholar

  56. 56.

    de Souza E Silva A; Pertille, A.; Reis Barbosa, C. G.; Aparecida de Oliveira Silva, J; de Jesus, D. V.; Ribeiro, A G S V; Baganha, R. J.; de Oliveira, J. J. Effects of Creatine Supplementation on Renal Function: A Systematic Review and Meta-Analysis. J. Ren. Nutr. 2019, 29, 480-489.

  57. 57.

    Gualano B, de Salles Painelli V, Roschel H, Lugaresi R, Dorea E, Artioli GG, Lima FR, da Silva ME, Cunha MR, Seguro AC, Shimizu MH, Otaduy MC, Sapienza MT, da Costa Leite C, Bonfa E, Lancha Junior AH. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur. J. Appl. Physiol. 2011;111:749–56.

    CAS  PubMed  Article  Google Scholar

  58. 58.

    Gualano B, Roschel H, Lancha AH, Brightbill CE, Rawson ES. In sickness and in health: the widespread application of creatine supplementation. Amino Acids. 2012;43:519–29.

    CAS  PubMed  Article  Google Scholar

  59. 59.

    Rawson ES, Clarkson PM, Tarnopolsky MA. Perspectives on Exertional Rhabdomyolysis. Sports Med. 2017;47:33–49.

    PubMed  PubMed Central  Article  Google Scholar

  60. 60.

    Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (Lond). 1992;83:367–74.

    CAS  Article  Google Scholar

  61. 61.

    van der Merwe J, Brooks NE, Myburgh KH. Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clin. J. Sport Med. 2009;19:399–404.

    PubMed  Article  Google Scholar

  62. 62.

    Ustuner ET. Cause of androgenic alopecia: crux of the matter. Plast. Reconstr. Surg. Glob Open. 2013;1:e64.

    PubMed  PubMed Central  Article  Google Scholar

  63. 63.

    Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. 2002;19:413–25.

    CAS  PubMed  Article  Google Scholar

  64. 64.

    Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp. Gerontol. 2002;37:981–90.

    CAS  PubMed  Article  Google Scholar

  65. 65.

    Vatani DS, Faraji H, Soori R, Mogharnasi M. The effects of creatine supplementation on performance and hormonal response in amateur swimmers. Science and Sports. 2011;26:272–7.

    Article  Google Scholar

  66. 66.

    Arazi H, Rahmaninia F, Hosseini K, Asadi A. Effects of short term creatine supplementation and resistance exercises on resting hormonal and cardiovascular responses. Science and Sports. 2015;30:105–9.

    Article  Google Scholar

  67. 67.

    Cook CJ, Crewther BT, Kilduff LP, Drawer S, Gaviglio CM. Skill execution and sleep deprivation: effects of acute caffeine or creatine supplementation - a randomized placebo-controlled trial. J. Int. Soc. Sports Nutr. 2011;8:2–2.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  68. 68.

    Cooke MB, Brabham B, Buford TW, Shelmadine BD, McPheeters M, Hudson GM, Stathis C, Greenwood M, Kreider R, Willoughby DS. Creatine supplementation post-exercise does not enhance training-induced adaptations in middle to older aged males. Eur. J. Appl. Physiol. 2014;114:1321–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  69. 69.

    Hoffman J, Ratamess N, Kang J, Mangine G, Faigenbaum A, Stout J. Effect of creatine and beta-alanine supplementation on performance and endocrine responses in strength/power athletes. Int. J. Sport Nutr. Exerc. Metab. 2006;16:430–46.

    CAS  PubMed  Article  Google Scholar

  70. 70.

    Volek JS, Ratamess NA, Rubin MR, Gomez AL, French DN, McGuigan MM, Scheett TP, Sharman MJ, Hakkinen K, Kraemer WJ. The effects of creatine supplementation on muscular performance and body composition responses to short-term resistance training overreaching. Eur. J. Appl. Physiol. 2004;91:628–37.

    CAS  PubMed  Article  Google Scholar

  71. 71.

    Rahimi R, Faraji H, Vatani DS, Qaderi M. Creatine supplementation alters the hormonal response to resistance exercise. Kinesiology. 2010;42:28–35.

    Google Scholar

  72. 72.

    Dalbo VJ, Roberts MD, Stout JR, Kerksick CM. Putting to rest the myth of creatine supplementation leading to muscle cramps and dehydration. Br. J. Sports Med. 2008;42:567–73.

    CAS  PubMed  Article  Google Scholar

  73. 73.

    Poortmans JR, Francaux M. Adverse effects of creatine supplementation: fact or fiction? Sports Med. 2000;30:155–70.

    CAS  PubMed  Article  Google Scholar

  74. 74.

    Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG, Kraemer WJ, Meyer RA, Spriet LL, Tarnopolsky MA, Wagenmakers AJ, Williams MH. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med. Sci Sports Exerc. 2000;32:706–17.

    CAS  PubMed  Article  Google Scholar

  75. 75.

    Kraemer WJ, Volek JS. Creatine supplementation. Its role in human performance. Clin. Sports Med. 1999;18:651–66 ix.

    CAS  Google Scholar

  76. 76.

    Deminice R, Rosa FT, Pfrimer K, Ferrioli E, Jordao AA, Freitas E. Creatine Supplementation Increases Total Body Water in Soccer Players: a Deuterium Oxide Dilution Study. Int. J. Sports Med. 2016;37:149–53.

    CAS  PubMed  Google Scholar

  77. 77.

    Greenwood M, Farris J, Kreider R, Greenwood L, Byars A. Creatine supplementation patterns and perceived effects in select division I collegiate athletes. Clin. J. Sport Med. 2000;10:191–4.

    CAS  PubMed  Article  Google Scholar

  78. 78.

    Greenwood M, Kreider RB, Melton C, Rasmussen C, Lancaster S, Cantler E, Milnor P, Almada A. Creatine supplementation during college football training does not increase the incidence of cramping or injury. Mol. Cell. Biochem. 2003;244:83–8.

    CAS  PubMed  Article  Google Scholar

  79. 79.

    Chang CT, Wu CH, Yang CW, Huang JY, Wu MS. Creatine monohydrate treatment alleviates muscle cramps associated with haemodialysis. Nephrol. Dial. Transplant. 2002;17:1978–81.

    CAS  PubMed  Article  Google Scholar

  80. 80.

    Unnithan VB, Veehof SH, Vella CA, Kern M. Is there a physiologic basis for creatine use in children and adolescents? J. Strength Cond Res. 2001;15:524–8.

    CAS  PubMed  Google Scholar

  81. 81.

    Hayashi AP, Solis MY, Sapienza MT, Otaduy MC, de Sa Pinto AL, Silva CA, Sallum AM, Pereira RM, Gualano B. Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial. Lupus. 2014;23:1500–11.

    CAS  PubMed  Article  Google Scholar

  82. 82.

    Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, Biggar D. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62:1771–7.

    CAS  PubMed  Article  Google Scholar

  83. 83.

    Sakellaris G, Kotsiou M, Tamiolaki M, Kalostos G, Tsapaki E, Spanaki M, Spilioti M, Charissis G, Evangeliou A. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. J. Trauma. 2006;61:322–9.

    CAS  PubMed  Article  Google Scholar

  84. 84.

    Kayton S, Cullen RW, Memken JA, Rutter R. Supplementation and ergogenic aid use by competitive male and female high school athletes. 2002;34:S193.

  85. 85.

    Diehl K, Thiel A, Zipfel S, Mayer J, Schnell A, Schneider S. Elite adolescent athletes' use of dietary supplements: characteristics, opinions, and sources of supply and information. Int. J. Sport Nutr. Exerc. Metab. 2012;22:165–74.

    CAS  PubMed  Article  Google Scholar

  86. 86.

    Gotshalk LA, Kraemer WJ, Mendonca MA, Vingren JL, Kenny AM, Spiering BA, Hatfield DL, Fragala MS, Volek JS. Creatine supplementation improves muscular performance in older women. Eur. J. Appl. Physiol. 2008;102:223–31.

    CAS  PubMed  Article  Google Scholar

  87. 87.

    Gotshalk LA, Volek JS, Staron RS, Denegar CR, Hagerman FC, Kraemer WJ. Creatine supplementation improves muscular performance in older men. Med. Sci. Sports Exerc. 2002;34:537–43.

    CAS  PubMed  Article  Google Scholar

  88. 88.

    Silva AJ, Machado Reis V, Guidetti L, Bessone Alves F, Mota P, Freitas J, Baldari C. Effect of creatine on swimming velocity, body composition and hydrodynamic variables. J. Sports Med. Phys. Fitness. 2007;47:58–64.

    CAS  PubMed  Google Scholar

  89. 89.

    Forbes SC, Sletten N, Durrer C, Myette-Cote E, Candow D, Little JP. Creatine Monohydrate Supplementation Does Not Augment Fitness, Performance, or Body Composition Adaptations in Response to Four Weeks of High-Intensity Interval Training in Young Females. Int. J. Sport Nutr. Exerc. Metab. 2017;27:285–92.

    CAS  PubMed  Article  Google Scholar

  90. 90.

    Antonio J, Ciccone V. The effects of pre versus post workout supplementation of creatine monohydrate on body composition and strength. J. Int. Soc. Sports Nutr. 2013;10:36–6 eCollection 2013.

  91. 91.

    Becque MD, Lochmann JD, Melrose DR. Effects of oral creatine supplementation on muscular strength and body composition. Med. Sci. Sports Exerc. 2000;32:654–8.

    CAS  PubMed  Article  Google Scholar

  92. 92.

    Chilibeck PD, Magnus C, Anderson M. Effect of in-season creatine supplementation on body composition and performance in rugby union football players. Appl. Physiol. Nutr. Metab. 2007;32:1052–7.

    PubMed  Article  Google Scholar

  93. 93.

    Volek JS, Duncan ND, Mazzetti SA, Staron RS, Putukian M, Gomez AL, Pearson DR, Fink WJ, Kraemer WJ. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Med. Sci. Sports Exerc. 1999;31:1147–56.

    CAS  PubMed  Article  Google Scholar

  94. 94.

    Chrusch MJ, Chilibeck PD, Chad KE, Davison KS, Burke DG. Creatine supplementation combined with resistance training in older men. Med. Sci. Sports Exerc. 2001;33:2111–7.

    CAS  PubMed  Article  Google Scholar

  95. 95.

    Gualano B, Macedo AR, Alves CR, Roschel H, Benatti FB, Takayama L, de Sa Pinto AL, Lima FR, Pereira RM. Creatine supplementation and resistance training in vulnerable older women: a randomized double-blind placebo-controlled clinical trial. Exp. Gerontol. 2014;53:7–15.

    CAS  PubMed  Article  Google Scholar

  96. 96.

    Candow DG, Vogt E, Johannsmeyer S, Forbes SC, Farthing JP. Strategic creatine supplementation and resistance training in healthy older adults. Appl. Physiol. Nutr. Metab. 2015;40:689–94.

    CAS  PubMed  Article  Google Scholar

  97. 97.

    Bourgeois JM, Nagel K, Pearce E, Wright M, Barr RD, Tarnopolsky MA. Creatine monohydrate attenuates body fat accumulation in children with acute lymphoblastic leukemia during maintenance chemotherapy. Pediatr. Blood Cancer. 2008;51:183–7.

    PubMed  Article  Google Scholar

  98. 98.

    Lobo DM, Tritto AC, da Silva LR, de Oliveira PB, Benatti FB, Roschel H, Niess B, Gualano B, Pereira RM. Effects of long-term low-dose dietary creatine supplementation in older women. Exp. Gerontol. 2015;70:97–104.

    CAS  PubMed  Article  Google Scholar

  99. 99.

    Sales LP, Pinto AJ, Rodrigues SF, Alvarenga JC, Goncalves N, Sampaio-Barros MM, Benatti FB, Gualano B, Rodrigues Pereira RM. Creatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial. J. Gerontol. A Biol. Sci. Med. Sci. 2020;75:931–8.

    CAS  PubMed  Article  Google Scholar

  100. 100.

    Forbes S, Candow D, Krentz J, Roberts M, Young K. Body fat changes following creatine supplementation and resistance training in adults > 50 years of age: A meta-analysis. Journal of Functional Morphology and Kinesiology. 2019;4:62.

    PubMed Central  Article  PubMed  Google Scholar

  101. 101.

    Hunter A. Monographs on biochemistry: creatine and creatinine. London: Longmans, Green and Co; 1928. p. 1.

    Google Scholar

  102. 102.

    Myers V. C.; Fine, M. S. The creatine content of muscle under normal conditions. Its relation to the urinary creatinine. J Biol Chem. 1913;14:9–26.

    CAS  Article  Google Scholar

  103. 103.

    Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am. J. Physiol. 1996;271:31.

    Google Scholar

  104. 104.

    Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am. J. Physiol. 1994;266:725.

    Google Scholar

  105. 105.

    Ostojic SM, Ahmetovic Z. Gastrointestinal distress after creatine supplementation in athletes: are side effects dose dependent? Res. Sports Med. 2008;16:15–22.

    PubMed  Article  Google Scholar

  106. 106.

    Gualano B, Artioli GG, Poortmans JR, Lancha Junior AH. Exploring the therapeutic role of creatine supplementation. Amino Acids. 2010;38:31–44.

    CAS  PubMed  Article  Google Scholar

  107. 107.

    Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.

    PubMed  Article  Google Scholar

  108. 108.

    Mcleod JC, Stokes T, Phillips SM. Resistance Exercise Training as a Primary Countermeasure to Age-Related Chronic Disease. Front. Physiol. 2019;10:645.

    PubMed  PubMed Central  Article  Google Scholar

  109. 109.

    Stout JR, Sue Graves B, Cramer JT, Goldstein ER, Costa PB, Smith AE, Walter AA. Effects of creatine supplementation on the onset of neuromuscular fatigue threshold and muscle strength in elderly men and women (64 - 86 years). J. Nutr. Health Aging. 2007;11:459–64.

    CAS  PubMed  Google Scholar

  110. 110.

    Canete S, San Juan AF, Perez M, Gomez-Gallego F, Lopez-Mojares LM, Earnest CP, Fleck SJ, Lucia A. Does creatine supplementation improve functional capacity in elderly women? J. Strength Cond Res. 2006;20:22–8.

    PubMed  Google Scholar

  111. 111.

    Baker TP, Candow DG, Farthing JP. Effect of Preexercise Creatine Ingestion on Muscle Performance in Healthy Aging Males. J. Strength Cond Res. 2016;30:1763–6.

    PubMed  Article  Google Scholar

  112. 112.

    Chami J, Candow DG. Effect of Creatine Supplementation Dosing Strategies on Aging Muscle Performance. J. Nutr. Health Aging. 2019;23:281–5.

    CAS  PubMed  Article  Google Scholar

  113. 113.

    Bermon S, Venembre P, Sachet C, Valour S, Dolisi C. Effects of creatine monohydrate ingestion in sedentary and weight-trained older adults. Acta Physiol. Scand. 1998;164:147–55.

    CAS  PubMed  Article  Google Scholar

  114. 114.

    Rawson ES, Wehnert ML, Clarkson PM. Effects of 30 days of creatine ingestion in older men. Eur. J. Appl. Physiol. Occup. Physiol. 1999;80:139–44.

    CAS  PubMed  Article  Google Scholar

  115. 115.

    Rawson ES, Clarkson PM. Acute creatine supplementation in older men. Int. J. Sports Med. 2000;21:71–5.

    CAS  PubMed  Article  Google Scholar

  116. 116.

    Wiroth JB, Bermon S, Andrei S, Dalloz E, Hebuterne X, Dolisi C. Effects of oral creatine supplementation on maximal pedalling performance in older adults. Eur. J. Appl. Physiol. 2001;84:533–9.

    CAS  PubMed  Article  Google Scholar

  117. 117.

    Branch JD. Effect of creatine supplementation on body composition and performance: a meta-analysis. Int. J. Sport Nutr. Exerc. Metab. 2003;13:198–226.

    CAS  PubMed  Article  Google Scholar

  118. 118.

    Devries MC, Phillips SM. Creatine supplementation during resistance training in older adults-a meta-analysis. Med. Sci. Sports Exerc. 2014;46:1194–203.

    CAS  PubMed  Article  Google Scholar

  119. 119.

    Candow DG, Chilibeck PD, Forbes SC. Creatine supplementation and aging musculoskeletal health. Endocrine. 2014;45:354–61.

    CAS  PubMed  Article  Google Scholar

  120. 120.

    Chilibeck PD, Chrusch MJ, Chad KE, Shawn Davison K, Burke DG. Creatine monohydrate and resistance training increase bone mineral content and density in older men. J. Nutr. Health Aging. 2005;9:352–3.

    CAS  PubMed  Google Scholar

  121. 121.

    Candow DG, Little JP, Chilibeck PD, Abeysekara S, Zello GA, Kazachkov M, Cornish SM, Yu PH. Low-dose creatine combined with protein during resistance training in older men. Med. Sci. Sports Exerc. 2008;40:1645–52.

    CAS  PubMed  Article  Google Scholar

  122. 122.

    Chilibeck PD, Candow DG, Landeryou T, Kaviani M, Paus-Jenssen L. Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women. Med. Sci. Sports Exerc. 2015;47:1587–95.

    CAS  PubMed  Article  Google Scholar

  123. 123.

    Green AL, Hultman E, Macdonald IA, Sewell DA, Greenhaff PL. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. Am. J. Physiol. 1996;271:821.

    Article  Google Scholar

  124. 124.

    Steenge GR, Simpson EJ, Greenhaff PL. Protein- and carbohydrate-induced augmentation of whole body creatine retention in humans. J. Appl. Physiol. (1985). 2000;89:1165–71.

    CAS  Article  Google Scholar

  125. 125.

    Kerksick CM, Wilborn CD, Roberts MD, Smith-Ryan A, Kleiner SM, Jager R, Collins R, Cooke M, Davis JN, Galvan E, Greenwood M, Lowery LM, Wildman R, Antonio J, Kreider RB. ISSN exercise & sports nutrition review update: research & recommendations. J. Int. Soc. Sports Nutr. 2018;15:38–y.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  126. 126.

    Cooke MB, Rybalka E, Williams AD, Cribb PJ, Hayes A. Creatine supplementation enhances muscle force recovery after eccentrically-induced muscle damage in healthy individuals. J. Int. Soc. Sports Nutr. 2009;6:13–3.

  127. 127.

    Santos RV, Bassit RA, Caperuto EC, Costa Rosa LF. The effect of creatine supplementation upon inflammatory and muscle soreness markers after a 30km race. Life Sci. 2004;75:1917–24.

    CAS  PubMed  Article  Google Scholar

  128. 128.

    Greenwood M, Kreider R, Earnest CP, Rasmussen C, Almada AL. Differences in creatine retention among three nutritional formulations of oral creatine supplements. Journal of Exercise Physiology Online. 2003;6:37–43.

    Google Scholar

  129. 129.

    Hespel P, Op't Eijnde B, Van Leemputte M, Urso B, Greenhaff PL, Labarque V, Dymarkowski S, Van Hecke P, Richter EA. Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. J. Physiol. 2001;536:625–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  130. 130.

    Op 't Eijnde, B.; Urso, B.; Richter, E. A.; Greenhaff, P. L.; Hespel, P. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. Diabetes 2001, 50, 18-23.

  131. 131.

    Kreider RB. Effects of creatine supplementation on performance and training adaptations. Mol. Cell. Biochem. 2003;244:89–94.

    CAS  PubMed  Article  Google Scholar

  132. 132.

    Kreider RB, Melton C, Rasmussen CJ, Greenwood M, Lancaster S, Cantler EC, Milnor P, Almada AL. Long-term creatine supplementation does not significantly affect clinical markers of health in athletes. Mol. Cell. Biochem. 2003;244:95–104.

    CAS  PubMed  Article  Google Scholar

  133. 133.

    Rosene JM, Whitman SA, Fogarty TD. A Comparison of Thermoregulation With Creatine Supplementation Between the Sexes in a Thermoneutral Environment. J. Athl Train. 2004;39:50–5.

    PubMed  PubMed Central  Google Scholar

  134. 134.

    Volek JS, Mazzetti SA, Farquhar WB, Barnes BR, Gomez AL, Kraemer WJ. Physiological responses to short-term exercise in the heat after creatine loading. Med. Sci. Sports Exerc. 2001;33:1101–8.

    CAS  PubMed  Article  Google Scholar

  135. 135.

    Watson G, Casa DJ, Fiala KA, Hile A, Roti MW, Healey JC, Armstrong LE, Maresh CM. Creatine use and exercise heat tolerance in dehydrated men. J. Athl Train. 2006;41:18–29.

    PubMed  PubMed Central  Google Scholar

  136. 136.

    Weiss BA, Powers ME. Creatine supplementation does not impair the thermoregulatory response during a bout of exercise in the heat. J. Sports Med. Phys. Fitness. 2006;46:555–63.

    CAS  PubMed  Google Scholar

  137. 137.

    Wright GA, Grandjean PW, Pascoe DD. The effects of creatine loading on thermoregulation and intermittent sprint exercise performance in a hot humid environment. J. Strength Cond Res. 2007;21:655–60.

    PubMed  Google Scholar

  138. 138.

    Beis LY, Polyviou T, Malkova D, Pitsiladis YP. The effects of creatine and glycerol hyperhydration on running economy in well trained endurance runners. J. Int. Soc. Sports Nutr. 2011;8:24–4.

  139. 139.

    Easton C, Turner S, Pitsiladis YP. Creatine and glycerol hyperhydration in trained subjects before exercise in the heat. Int. J. Sport Nutr. Exerc. Metab. 2007;17:70–91.

    CAS  PubMed  Article  Google Scholar

  140. 140.

    Easton C, Calder A, Prior F, Dobinson S, I'Anson R, MacGregor R, Mohammad Y, Kingsmore D, Pitsiladis YP. The effects of a novel "fluid loading" strategy on cardiovascular and haematological responses to orthostatic stress. Eur. J. Appl. Physiol. 2009;105:899–908.

    PubMed  Article  Google Scholar

  141. 141.

    Kilduff LP, Georgiades E, James N, Minnion RH, Mitchell M, Kingsmore D, Hadjicharlambous M, Pitsiladis YP. The effects of creatine supplementation on cardiovascular, metabolic, and thermoregulatory responses during exercise in the heat in endurance-trained humans. Int. J. Sport Nutr. Exerc. Metab. 2004;14:443–60.

    CAS  PubMed  Article  Google Scholar

  142. 142.

    Polyviou TP, Easton C, Beis L, Malkova D, Takas P, Hambly C, Speakman JR, Koehler K, Pitsiladis YP. Effects of glycerol and creatine hyperhydration on doping-relevant blood parameters. Nutrients. 2012;4:1171–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  143. 143.

    Polyviou TP, Pitsiladis YP, Lee WC, Pantazis T, Hambly C, Speakman JR, Malkova D. Thermoregulatory and cardiovascular responses to creatine, glycerol and alpha lipoic acid in trained cyclists. J. Int. Soc. Sports Nutr. 2012;9:29–9.

  144. 144.

    Polyviou TP, Pitsiladis YP, Celis-Morales C, Brown B, Speakman JR, Malkova D. The Effects of Hyperhydrating Supplements Containing Creatine and Glucose on Plasma Lipids and Insulin Sensitivity in Endurance-Trained Athletes. J. Amino Acids. 2015;2015:352458.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  145. 145.

    Lopez RM, Casa DJ, McDermott BP, Ganio MS, Armstrong LE, Maresh CM. Does creatine supplementation hinder exercise heat tolerance or hydration status? A systematic review with meta-analyses. J. Athl Train. 2009;44:215–23.

    PubMed  PubMed Central  Article  Google Scholar

  146. 146.

    Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M, Ziegenfuss T, Lopez H, Landis J, Antonio J. International Society of Sports Nutrition position stand: creatine supplementation and exercise. J. Int. Soc. Sports Nutr. 2007;4:6–6.

    PubMed  PubMed Central  Article  Google Scholar

  147. 147.

    Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst. Rev. 2013;6:CD004760 doi, CD004760.

    Google Scholar

  148. 148.

    Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly. Curr. Opin. Clin. Nutr. Metab. Care. 2000;3:497–502.

    CAS  PubMed  Article  Google Scholar

  149. 149.

    Tarnopolsky MA. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell. Biochem. 2007;46:183–204.

    PubMed  Article  Google Scholar

  150. 150.

    Hausmann ON, Fouad K, Wallimann T, Schwab ME. Protective effects of oral creatine supplementation on spinal cord injury in rats. Spinal Cord. 2002;40:449–56.

    CAS  PubMed  Article  Google Scholar

  151. 151.

    Rabchevsky AG, Sullivan PG, Fugaccia I, Scheff SW. Creatine diet supplement for spinal cord injury: influences on functional recovery and tissue sparing in rats. J. Neurotrauma. 2003;20:659–69.

    PubMed  Article  Google Scholar

  152. 152.

    Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stockler-Ipsiroglu G, Wallimann T, Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 2007;27:452–9.

    CAS  PubMed  Article  Google Scholar

  153. 153.

    Adcock KH, Nedelcu J, Loenneker T, Martin E, Wallimann T, Wagner BP. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev. Neurosci. 2002;24:382–8.

    CAS  PubMed  Article  Google Scholar

  154. 154.

    Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 2004;24:5909–12.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  155. 155.

    Allah Yar R, Akbar A, Iqbal F. Creatine monohydrate supplementation for 10 weeks mediates neuroprotection and improves learning/memory following neonatal hypoxia ischemia encephalopathy in female albino mice. Brain Res. 2015;1595:92–100.

    CAS  PubMed  Article  Google Scholar

  156. 156.

    Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 2000;48:723–9.

    CAS  PubMed  Article  Google Scholar

  157. 157.

    Brosnan JT, Brosnan ME. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu. Rev. Nutr. 2007;27:241–61.

    CAS  PubMed  Article  Google Scholar

  158. 158.

    Delanghe J, De Slypere JP, De Buyzere M, Robbrecht J, Wieme R, Vermeulen A. Normal reference values for creatine, creatinine, and carnitine are lower in vegetarians. Clin. Chem. 1989;35:1802–3.

    CAS  PubMed  Article  Google Scholar

  159. 159.

    Kalhan SC, Gruca L, Marczewski S, Bennett C, Kummitha C. Whole body creatine and protein kinetics in healthy men and women: effects of creatine and amino acid supplementation. Amino Acids. 2016;48:677–87.

    CAS  PubMed  Article  Google Scholar

  160. 160.

    Parise, G.; Mihic, S.; MacLennan, D.; Yarasheski, K. E.; Tarnopolsky, M. A. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J. Appl. Physiol. (1985) 2001, 91, 1041-1047.

  161. 161.

    Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med. Sci. Sports Exerc. 2000;32:291–6.

    CAS  PubMed  Article  Google Scholar

  162. 162.

    Bundey S, Crawley JM, Edwards JH, Westhead RA. Serum creatine kinase levels in pubertal, mature, pregnant, and postmenopausal women. J. Med. Genet. 1979;16:117–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  163. 163.

    King B, Spikesman A, Emery AE. The effect of pregnancy on serum levels of creatine kinase. Clin. Chim. Acta. 1972;36:267–9.

    CAS  PubMed  Article  Google Scholar

  164. 164.

    Ellery SJ, Dickinson H, McKenzie M, Walker DW. Dietary interventions designed to protect the perinatal brain from hypoxic-ischemic encephalopathy--Creatine prophylaxis and the need for multi-organ protection. Neurochem. Int. 2016;95:15–23.

    CAS  PubMed  Article  Google Scholar

  165. 165.

    Dickinson H, Davies-Tuck M, Ellery SJ, Grieger JA, Wallace EM, Snow RJ, Walker DW, Clifton VL. Maternal creatine in pregnancy: a retrospective cohort study. BJOG. 2016;123:1830–8.

    CAS  PubMed  Article  Google Scholar

  166. 166.

    Ellery SJ, LaRosa DA, Kett MM, Della Gatta PA, Snow RJ, Walker DW, Dickinson H. Maternal creatine homeostasis is altered during gestation in the spiny mouse: is this a metabolic adaptation to pregnancy? BMC Pregnancy Childbirth. 2015;15:92–1.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  167. 167.

    Dickinson H, Ellery S, Ireland Z, LaRosa D, Snow R, Walker DW. Creatine supplementation during pregnancy: summary of experimental studies suggesting a treatment to improve fetal and neonatal morbidity and reduce mortality in high-risk human pregnancy. BMC Pregnancy Childbirth. 2014;14:150–0.

  168. 168.

    Ireland Z, Castillo-Melendez M, Dickinson H, Snow R, Walker DW. A maternal diet supplemented with creatine from mid-pregnancy protects the newborn spiny mouse brain from birth hypoxia. Neuroscience. 2011;194:372–9.

    CAS  PubMed  Article  Google Scholar

  169. 169.

    De Guingand DL, Ellery SJ, Davies-Tuck ML, Dickinson H. Creatine and pregnancy outcomes, a prospective cohort study in low-risk pregnant women: study protocol. BMJ Open. 2019;9:e026756–6.

  170. 170.

    Riehemann S, Volz HP, Wenda B, Hubner G, Rossger G, Rzanny R, Sauer H. Frontal lobe in vivo (31)P-MRS reveals gender differences in healthy controls, not in schizophrenics. NMR Biomed. 1999;12:483–9.

    CAS  PubMed  Article  Google Scholar

  171. 171.

    Kondo DG, Forrest LN, Shi X, Sung YH, Hellem TL, Huber RS, Renshaw PF. Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids. 2016;48:1941–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar

  172. 172.

    Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF. Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J. Dual Diagn. 2015;11:189–202.

    PubMed  PubMed Central  Article  Google Scholar

  173. 173.

    Bebbington PE, Dunn G, Jenkins R, Lewis G, Brugha T, Farrell M, Meltzer H. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol. Med. 1998;28:9–19.

    CAS  PubMed  Article  Google Scholar

  174. 174.

    Kuehner C. Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr. Scand. 2003;108:163–74.

    CAS  PubMed  Article  Google Scholar

  175. 175.

    Lyoo IK, Kong SW, Sung SM, Hirashima F, Parow A, Hennen J, Cohen BM, Renshaw PF. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res. 2003;123:87–100.

    CAS  PubMed  Article  Google Scholar

  176. 176.

    Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Vangerven L, Hespel P. Long-term creatine intake is beneficial to muscle performance during resistance training. J. Appl. Physiol. (1985). 1997;83:2055–63.

    CAS  Article  Google Scholar

  177. 177.

    Cox G, Mujika I, Tumilty D, Burke L. Acute creatine supplementation and performance during a field test simulating match play in elite female soccer players. Int. J. Sport Nutr. Exerc. Metab. 2002;12:33–46.

    CAS  PubMed  Article  Google Scholar

  178. 178.

    Hamilton KL, Meyers MC, Skelly WA, Marley RJ. Oral creatine supplementation and upper extremity anaerobic response in females. Int. J. Sport Nutr. Exerc. Metab. 2000;10:277–89.

    CAS  PubMed  Article  Google Scholar

  179. 179.

    Kambis KW, Pizzedaz SK. Short-term creatine supplementation improves maximum quadriceps contraction in women. Int. J. Sport Nutr. Exerc. Metab. 2003;13:87–96.

    CAS  PubMed  Article  Google Scholar

  180. 180.

    Smith-Ryan AE, Ryan ED, Fukuda DH, Costa PB, Cramer JT, Stout JR. The effect of creatine loading on neuromuscular fatigue in women. Med. Sci. Sports Exerc. 2014;46:990–7.

    CAS  PubMed  Article  Google Scholar

  181. 181.

    Aguiar, A. F.; Januario, R. S.; Junior, R. P.; Gerage, A. M.; Pina, F. L.; do Nascimento, M. A.; Padovani, C. R.; Cyrino, E. S. Long-term creatine supplementation improves muscular performance during resistance training in older women. Eur. J. Appl. Physiol. 2013, 113, 987-996.

  182. 182.

    Greenhaff, P. L.; Casey, A.; Short, A. H.; Harris, R.; Soderlund, K.; Hultman, E. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin. Sci. (Lond) 1993, 84, 565-571.

  183. 183.

    Wyss M, Braissant O, Pischel I, Salomons GS, Schulze A, Stockler S, Wallimann T. Creatine and creatine kinase in health and disease--a bright future ahead? Subcell. Biochem. 2007;46:309–34.

    PubMed  Article  Google Scholar

  184. 184.

    Wallimann T, Riek U, Moddel M. Intradialytic creatine supplementation: A scientific rationale for improving the health and quality of life of dialysis patients. Med. Hypotheses. 2017;99:1–14.

    CAS  PubMed  Article  Google Scholar

  185. 185.

    Deldicque L, Decombaz J, Zbinden Foncea H, Vuichoud J, Poortmans JR, Francaux M. Kinetics of creatine ingested as a food ingredient. Eur. J. Appl. Physiol. 2008;102:133–43.

    CAS  PubMed  Article  Google Scholar

  186. 186.

    Persky AM, Brazeau GA, Hochhaus G. Pharmacokinetics of the dietary supplement creatine. Clin. Pharmacokinet. 2003;42:557–74.

    CAS  PubMed  Article  Google Scholar

  187. 187.

    Jager R, Purpura M, Shao A, Inoue T, Kreider RB. Analysis of the efficacy, safety, and regulatory status of novel forms of creatine. Amino Acids. 2011;40:1369–83.

    PubMed  PubMed Central  Article  CAS  Google Scholar

  188. 188.

    Negrisoli G, Del Corona L. Hydrosoluble organic salts of creatine; Italy; 1997. p. 1.

    Google Scholar

  189. 189.

    Pischel, I.; Weiss, S. New creatine pyruvate derivatives from crystallization in polar solvents; Germany, 1996; , pp 1.

  190. 190.

    Pischel, I. Creatine ascorbates and a method of producing them; United States, 1999; , pp 1.

  191. 191.

    Abraham, S.; Jiang, S. Process for preparing a creatine heterocyclic acid salt and method of use; United States, 2005; , pp 1.

  192. 192.

    Child, R.; Tallon, M. J. In In Creatine ethyl ester rapidly degrades to creatinine in stomach acid; International Society of Sports Nutrition 4th Annual Meeting; Las Vegas, NV, 2007; .

  193. 193.

    Giese MW, Lecher CS. Non-enzymatic cyclization of creatine ethyl ester to creatinine. Biochem. Biophys. Res. Commun. 2009;388:252–5.

    CAS  PubMed  Article  Google Scholar

  194. 194.

    Dalton RL, Sowinski RJ, Grubic TJ, Collins PB, Coletta AM, Reyes AG, Sanchez B, Koozehchian M, Jung YP, Rasmussen C, Greenwood M, Murano PS, Earnest CP, Kreider RB. Hematological and Hemodynamic Responses to Acute and Short-Term Creatine Nitrate Supplementation. Nutrients. 2017;9. https://doi.org/10.3390/nu9121359.

  195. 195.

    Galvan, E.; Walker, D. K.; Simbo, S. Y.; Dalton, R.; Levers, K.; O'Connor, A.; Goodenough, C.; Barringer, N. D.; Greenwood, M.; Rasmussen, C.; Smith, S. B.; Riechman, S. E.; Fluckey, J. D.; Murano, P. S.; Earnest, C. P.; Kreider, R. B. Acute and chronic safety and efficacy of dose dependent creatine nitrate supplementation and exercise performance. J. Int. Soc. Sports Nutr. 2016, 13, 12-0. eCollection 2016.

  196. 196.

    Kreider R, Willoughby D, Greenwood M, Parise G, Payne E, Tarnopolsky M. Effects of serum creatine supplementation on muscle creatine content. Journal of Exercise Physiology Online. 2003;6:24–33.

    Google Scholar

  197. 197.

    Pischel I, Gastner T. Creatine--its chemical synthesis, chemistry, and legal status. Subcell. Biochem. 2007;46:291–307.

    PubMed  Article  Google Scholar

  198. 198.

    Howard AN, Harris RC. Compositions containing creatine; USP Office Editor: United States; 1999.

    Google Scholar

  199. 199.

    Edgar G, Shiver HE. The equilibrium between creatine and creatinine, in aqueous solution: the effect of hydrogen ion. J Am Chem Soc. 1925;47:1179–88.

    CAS  Article  Google Scholar

  200. 200.

    Cannon JG, Orencole SF, Fielding RA, Meydani M, Meydani SN, Fiatarone MA, Blumberg JB, Evans WJ. Acute phase response in exercise: interaction of age and vitamin E on neutrophils and muscle enzyme release. Am. J. Physiol. 1990;259:1214.

    Google Scholar

Download references

Acknowledgments

Not applicable.

Author information

Affiliations

  1. Department of Health and Human Performance, Nova Southeastern University, Davie, Florida, USA

    Jose Antonio

  2. Faculty of Kinesiology and Health Studies, University of Regina, Regina, Canada

    Darren G. Candow

  3. Department of Physical Education, Faculty of Education, Brandon University, Brandon, MB, Canada

    Scott C. Forbes

  4. Applied Physiology & Nutrition Research Group; School of Medicine, FMUSP, University of Sao Paulo, Sao Paulo, SP, Brazil

    Bruno Gualano

  5. Sports Medicine Department, Mayo Clinic Health System, La Crosse, WI, USA

    Andrew R. Jagim

  6. Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department of Health & Kinesiology, Texas A&M University, College Station, USA

    Richard B. Kreider

  7. Department of Health, Nutrition, and Exercise Science, Messiah University, Mechanicsburg, PA, USA

    Eric S. Rawson

  8. Department of Exercise and Sport Science, University of North Carolina, Chapel Hill, NC, USA

    Abbie E. Smith-Ryan

  9. Department of Exercise Science and Sport Management, Kennesaw State University, Kennesaw, GA, USA

    Trisha A. VanDusseldorp

  10. School of Exercise and Sport Science, University of Mary Hardin-Baylor, Belton, TX, USA

    Darryn S. Willoughby

  11. The Center for Applied Health Sciences, Canfield, Ohio, USA

    Tim N. Ziegenfuss

Contributions

Conceptualization: DGC; Writing-original draft preparation: All authors. The authors declare that the content of this paper has not been published or submitted for publication elsewhere. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Jose Antonio.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable

Competing interests

JA is Chief Executive Officer of the ISSN, an academic non-profit that receives support and/or sponsorship from companies that manufacture and/or sell creatine or creatine-containing products.

DGC has received research grants and performed industry sponsored research involving creatine supplementation, received creatine donation for scientific studies and travel support for presentations involving creatine supplementation at scientific conferences. In addition, DGC serves on the Scientific Advisory Board for Alzchem (a company which manufactures creatine) and the editorial review board for the Journal of the International Society of Sports Nutrition and is a sports science advisor to the ISSN. Furthermore, DGC has previously served as the Chief Scientific Officer for a company that sells creatine products.

SCF has served as a scientific advisor for a company that sells creatine products.

BG has received research grants, creatine donation for scientific studies, travel support for participation in scientific conferences (includes the ISSN) and honorarium for speaking at lectures from AlzChem (a company which manufactures creatine). In addition, BG serves on the Scientific Advisory Board for Alzchem (a company that manufactures creatine).

ARJ has consulted with and received external funding from companies that sell certain dietary ingredients and also writes for online and other media outlets on topics related to exercise and nutrition

RBK is co-founder and member of the board of directors for the ISSN. In addition, RBK has conducted industry sponsored research on creatine, received financial support for presenting on creatine at industry sponsored scientific conferences (includes the ISSN), and served as an expert witness on cases related to creatine. Additionally, he serves as Chair of the Scientific Advisory Board for Alzchem that manufactures creatine monohydrate.

ESR serves on the Scientific Advisory Board for Alzchem (a company which manufactures creatine). In addition, ESR received financial compensation to deliver the President's Lecture on creatine supplementation at the 2019 ISSN annual conference.

AESR has received research funding from industry sponsors related to sports nutrition products and ingredients. In addition, AESR serves on the Scientific Advisory Board for Alzchem (a company that manufactures creatine).

TAV has received funding to study creatine and is an advisor for supplement companies who sell creatine. In addition, TAV is the current president of the ISSN.

DSW serves as a scientific advisor to the ISSN and on the editorial review board for the Journal of the International Society of Sports Nutrition. In addition, DSW is Past President of the ISSN and has received financial compensation from the ISSN to speak about creatine supplementation.

TNZ has conducted industry sponsored research involving creatine supplementation and has received research funding from industry sponsors related to sports nutrition products and ingredients. In addition, TNZ serves on the editorial review board for the Journal of the International Society of Sports Nutrition and is Past President of the ISSN.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Antonio, J., Candow, D.G., Forbes, S.C. et al. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?. J Int Soc Sports Nutr 18, 13 (2021). https://doi.org/10.1186/s12970-021-00412-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI : https://doi.org/10.1186/s12970-021-00412-w

Keywords

  • Social Media
  • Anecdotal
  • Research
  • Adverse Effects
  • Safety

Will Creatine Boost Testosterone

Source: https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00412-w

Share:
 
banner